ࡱ>  bjbj}} \rNN$P#$1X$%d("((()f?lE8$;ֶ I)) I Iֶ((4OOO I((O IOOJ(m8wIB01ȤVZL"@8x$ I IO I I I I IֶֶN I I I1 I I I I I I I I I I I I IN n: Saint ˻ֱ University Institutional Review Board Behavioral & Social Sciences (Non-Clinical) Informed Consent Template GUIDELINES FOR PREPARING AN INFORMED CONSENT DOCUMENT INFORMED CONSENT MODEL TEMPLATE: Always use the current version of the informed consent model template when preparing your consent form. In order to make sure that you are using the current version, go to the SLU IRB website and click on Forms and Instructions. Note: ˻ֱ that involves the collection, use, or disclosure of Protected Health Information (PHI) is subject to HIPAA requirements. A separate authorization for use of PHI must be obtained using the new SLU model  HYPERLINK "/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/hipaa_authorization_form.doc" HIPAA Authorization Form. FORMAT: The informed consent document should meet the following format requirements: All consent form documents must be typed using a black 12 point font (preferably Arial or Times New Roman). If your research study population requires a larger font, adjust the font accordingly. Number all pages of the consent document. Include version date in the footer in the lower left corner of each page. Place each section heading directly above the text to which it refers. Do not let headings stand alone at the bottom of the page, or with only part of a sentence attached. Before submitting the consent form to the IRB for review, please print and review the document for print errors, spelling and grammar, font sizes, floating headings, etc. Delete any instructions/instruction boxes. CONSENT FORM LANGUAGE AND READABILITY: The consent document you prepare is a reflection of your communication with your research participants. Because research participants come from a variety of backgrounds and educational levels and may be under physical or emotional stress, it is important that your consent document is easy to understand. Because studies have shown that understanding decreases with the length of the text, the consent document should be written at an 8th grade reading level. Microsoft Word has a readability check (under Tools, Spelling and Grammar, Options, check show readability statistics). Below are some helpful hints for writing a consent form that is easy to read and understand: Speak to your reader. Use you to refer to the subject. Use the active voice to make it clear who will do what. For example, write, You must provide consent not, Consent must be provided. Use words with the fewest number of syllables. For example, use take part rather than participate. Use short, declarative sentences to deliver a clear message. Break long sentences into several shorter ones. Express only one major idea per sentence. Break lengthy paragraphs into multiple, shorter paragraphs. Break long paragraphs into several shorter ones. Express only one major idea per paragraph. Avoid unfamiliar or confusing words or phrases. Avoid jargon. Use lay language (non-technical) in place of scientific terminology. For example, survey or questionnaire should be used instead of instrument or assessment. If scientific terminology is essential, include a lay language definition. GENERAL INSTRUCTIONS FOR USING THIS FORM: This Model Consent Form template includes shaded boxes providing brief instructions for completing the required elements of an informed consent document. Sample consent language is provided at the end of the template, and also linked by topic within the instructional boxes. The instructions are shaded so you can tell the difference between instructions and required language. Delete all shaded instruction boxes and underlined instructional text BEFORE submitting this form to the SLU IRB for review. To delete the instruction boxes, place your curser within the shaded box, right click the mouse, and select Delete Rows. To delete the underlined text, select the text by highlighting with your mouse, and push the delete button on your keyboard. Instructions for the consent form header below: List all sites (under SLU IRB jurisdiction) in which the research study will take place below SAINT LOUIS UNIVERSITY. List any SSM Health sites and list SSM Health Saint ˻ֱ University Hospital if in-patient. The model consent should be printed on Saint ˻ֱ University letterhead when appropriate. Insert the IRB # obtained from eIRB before uploading consent in the system. The Title of Project should match the protocol title. This title should also match the sponsor contract or grant title if appropriate. SAINT LOUIS UNIVERSITY ˻ֱ Study Consent Form STUDY TITLE: [Title from protocol]  This consent form contains important information to help you decide whether to participate in a research study. The study staff will explain this study to you. Ask questions about anything that is not clear at any time. You may take home an unsigned copy of this consent form to think about and discuss with family or friends. Being in a study is voluntary your choice. If you join this study, you can still stop at any time. No one can promise that a study will help you. Do not join this study unless all of your questions are answered. After reading and discussing the information in this consent form you should know: Why this research study is being done; What will happen during the study; Any possible benefits to you; The possible risks to you; Other options you could choose instead of being in this study; Whether being in this study could involve any cost to you; and What to do if you have problems or questions about this study. Please read this consent form carefully. RESEARCH STUDY CONSENT FORM Participant: IRB #:First Name / Last NamePrincipal Investigator (PI)Contact Phone #First Name / Last Name CredentialsTitle of Project:  INSTRUCTIONS: The first paragraph of your consent form is to introduce the research study to the participant. Modify the paragraph below to fit your research study. For samples of text that can be cut/pasted into this section of the consent form, click here:  HYPERLINK \l "introduction" INTRODUCTION You refers to the person who takes part in the research study. You are being asked to take part in a research study conducted by name of principal investigator and colleagues because include a reason for why the subject is being asked to participate in the research study (e.g., you are being asked to participate in a research study because you have a twin sibling). This consent document may contain words that you do not understand. Please ask the researcher to explain anything that you do not understand. INSTRUCTIONS: This section of the informed consent document is required for studies approved by the SLU IRB on or after 1/21/19. This section may be deleted if this informed consent document as a whole is 5 pages or less in length, at 12 point font. The federal regulations require that informed consent documents contain a concise and focused presentation of key study information. The intention of this section is to provide potential research participants with a better understanding of the projects scope, including major risks and benefits, so they can make a more fully informed decision about whether to participate. The key information must be presented first and should be limited to 1 page in length, and then the information may be discussed in greater detail later in the informed consent document. Examples of key information sections may be found  HYPERLINK "/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/consent_key_information_examples.docx" HERE.  Key Information for You to Consider Purpose. The purpose of this research is [provide a brief description of why the research is being conducted, no more than 2-3 sentences]. Duration. It is expected that your participation will last [expected duration]. Study Procedures. You will be asked to [briefly highlight the key research procedures]. Risks. Some of the foreseeable risks or discomforts of your participation include [describe the most important and significant risks to the participant. Consider those most probable and/or highest magnitude of harm]. Benefits. Some of the benefits that may be expected include [insert direct benefits, or if no direct benefit to subject state there is no direct benefit, but the researchers hope to learn/gain xyz]. Alternatives. You may choose not to be in this research study. As an alternative to participation, you could [note appropriate alternative procedures or courses of treatment, if any, that might be advantageous to the prospective participant. If there are no alternatives, state, Participation is voluntary and the only alternative is to not participate.].  WHY IS THIS RESEARCH STUDY BEING DONE? INSTRUCTIONS: This section of the informed consent document should briefly describe: Main purpose of the research study Background information in lay language that informs and justifies why the research study is being performed so the participant can understand why the research study is important. The maximum number of participants expected to be involved at SLU for the duration of the study. If the study is also taking place at other sites, state the total number to be recruited at SLU and the total number to be recruited at all sites. This number should match the numbers stated in your IRB Application. For studies that involve deception,  HYPERLINK \l "Deception" CLICK HERE for further instructions. WHAT AM I BEING ASKED TO DO? INSTRUCTIONS: This section of the informed consent document should clearly describe for the participant their involvement in the study. Include the following information, when applicable: Describe the procedures that the participant will undergo. If more than one appointment is necessary, then describe the procedures broken down by each participant appointment. If possible, organize this information in chronological order, and use headers and bullet points to list different procedures. The use of tables and charts may also be helpful for the participant if the study is very involved. If applicable, identify procedures that are a standard part of a program/appointment, and which procedures are experimental and would not take place other than for purposes of this study. (e.g., as part of a normal visit, clients will complete the new client questionnaire; however, study participants will also be asked to complete nutrition, mental health, and physical activity surveys). Include information about the study design, i.e., randomization. If randomization will occur, explain that the participants will be assigned to one of the groups by chance and state what the chances are of being in each group (give the number or a percentage). If photographs, audiotapes, or videotapes will be generated as part of the research study, provide details about the content and procedures. Permission to contact participants for future research studies should be requested in this section if applicable. Click Future Use of Data bullet point link below for an example. For samples of consent form language that can be cut/pasted into this section, click on one of the following options:  HYPERLINK \l "ParticipatinginOtherStudies" Participating in Other Studies  HYPERLINK \l "Screeningprocedures" Screening Procedures  HYPERLINK \l "interviewquestionnaire"   HYPERLINK \l "followup" Follow-Up Visits Interviews/Questionnaires  HYPERLINK \l "AudioVideo" ˻ֱ Involving Photographs/Audiotapes/Videotapes  HYPERLINK \l "futureuse" Future Use of Data For studies that involve the collection of identifiable data or identifiable biospecimens, one of the following statements MUST be included: Identifiers might be removed from your data (and/or samples) collected in this research, and used for future research studies or distributed to other researchers for future research studies (with/without) your additional permission. Your data (and/or samples) collected as part of this research, even if identifiers are removed, will not be used or distributed for future research studies. HOW LONG WILL I BE IN THE RESEARCH STUDY? INSTRUCTIONS: This section should explain: The anticipated time commitment expected from the participant. (Provide duration such as hours, days, months, years, followed for life; or give a range, e.g., 2-5 years). Total time expected for researchers to complete the research activities.  The time you may spend on this research study is The research study should be completed by WHAT ARE THE RISKS? INSTRUCTIONS: In this section of the consent document, potential risks to the participant should be addressed. This information should be limited to those risks and discomforts associated with the procedures or activities done for research purposes. Include the following information in this section: Reasonably foreseeable risks or discomforts resulting from taking part in the research study. The possibility of embarrassment, loss of privacy, financial burden, adverse impact on employment, etc. should be considered as risks and included. If appropriate, state that there may be risks that are unforeseen or unknown at this time. Indicate how risks and discomforts will be minimized. For samples of consent form language that can be cut/pasted into this section, click on one of the following options:  HYPERLINK \l "interview" Interviews/Questionnaires HYPERLINK \l "breach"Breach of Confidentiality-Sensitive Issues  HYPERLINK \l "breachCertConf" Breach of Confidentiality Sensitive Issues requiring a Certificate of Confidentiality There are certain risks and discomforts that may occur if you take part in this research study. They include To try to prevent these risks, the researcher (or insert name of PI) will. If discomforts occur, the researcher (or insert name of PI) will try to help these by As this study involves the use of your personal information, there is a chance that a loss of confidentiality will occur. The researchers have procedures in place to lessen the possibility of this happening, as described in section 7 of this form. The researcher is willing to discuss any questions you might have about these risks and discomforts. 5. ARE THERE BENEFITS TO BEING IN THIS RESEARCH STUDY? INSTRUCTIONS: In this section, describe the benefits, or lack of benefits, to the individual as well as to society. The first sentence should indicate that the participant may not/will not benefit from the research study. NOTE: Compensation for time or reimbursement for expenses are not considered benefits and should be included in the Cost section (section 8 of the consent document). For samples of text that can be cut/pasted into this section of the consent form, click here:  HYPERLINK \l "benefits" BENEFITS  You (may not/will not) benefit from this research study. The possible benefits to you are Even though you may not receive any benefit, (society / other people with / other people who) may benefit in the future because of what the researchers learn from this research study. 6. WHAT OTHER OPTIONS ARE THERE? INSTRUCTIONS: This section of the consent form should include (if applicable): The standard procedures for the participant (if different from the research study procedures) If no alternatives exist, state, You may choose not to be in this research study. You may choose not to be in this research study. 7. WILL MY INFORMATION BE KEPT PRIVATE? INSTRUCTIONS: It is a federal requirement to describe the extent, if any, to which confidentiality of records identifying the participants will be maintained. In this section, describe the following: Specific method for assuring confidentiality (this section should match the eIRB application). Indicate where study records will be kept, how they will be maintained, and how the researcher will be responsible for them. Indicate who will have access to the confidential information. Disclose whether data will be sent to collaborators outside of SLU. If videotaping or audio taping is done, indicate how confidentiality of the tapes will be maintained and when they will be destroyed. For samples of consent form language that can be cut/pasted into this section, click on one of the following options:  HYPERLINK \l "resereccontid" ˻ֱ Records Containing Identifiers  HYPERLINK \l "datasharing" Data Sharing (should be consistent with the eIRB application)  HYPERLINK \l "releaseofresearchresults" Release of Individual ˻ֱ Results  HYPERLINK \l "MandatedReport" Mandated Reporter Language  HYPERLINK \l "COC" Certificate of Confidentiality (REQUIRED language if this is NIH funded research) The results of the research study may be published, but your name or identity will not be revealed and your information will remain private. In order to protect your information, the researcher (or insert name of PI) will... The Saint ˻ֱ University Institutional Review Board (the Board that is responsible for protecting the welfare of persons who take part in research studies), (insert hospital name officials) or other University officials may review your research study records. The research Sponsor, (list name if study has a sponsor, otherwise delete this sentence), may also review your study records. State or federal laws or court orders may also require that information from your research study records be released. For studies that may produce clinically relevant research results, including individual research results, describe whether the results will be given to the participants: As this research study involves health tests, the research team could find out information that affects your health during the course of this study. The researchers (plan/do not plan) to provide you with this information. (Please modify this statement, and include under what conditions the participant would/would not be given the research results). For  HYPERLINK "/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/nih_clinical_trial_definition.docx" NIH sponsored clinical trials (e.g., behavioral Interventions with health related outcomes), the following statement must be included: Note - For each clinical trial conducted or supported by a Federal department or agency, an IRB approved consent form must be posted on the Federal website after the clinical trial is closed to recruitment, and no later than 60 days after the last study visit by any subject, as required by the protocol A description of this study and study results will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This website will not include information that can identify you. You can search this website at any time. 8. WHAT ARE THE COSTS AND PAYMENTS? INSTRUCTIONS: In this section of the consent form, please describe the following (where applicable): State who will be responsible for the costs of procedures, follow-up tests, office visits, treatment of adverse events, etc. relating to research activities. State what costs are additional. (Differentiate between costs for standard procedures and costs resulting from taking part in the research study). State whether or not the subject is receiving an incentive/compensation (i.e. payments, gift cards, travel reimbursements, etc.) Note, for research studies involving more than one interaction (appointment/visit), payment must be prorated. State how and when participants will be paid. Payments must comply with the Universitys Policy on Participant Payments within ˻ֱ and/or Sponsored Activities (Participant Payment Cards should be used for single payments greater than $25 or total payments exceeding $100 in a calendar year unless an exception was granted). For samples of consent form language that can be cut/pasted into this section, click on the following options:  HYPERLINK \l "costsandpayment" ˻ֱer/Sponsor Covers all Costs  HYPERLINK \l "payment" Payment In this study you will/will not be paid For studies using Participant Payment Cards (i.e. CCPay, ClinCard) include: Payments for taking part in this research study will be put onto a participant payment card. The participant payment card is managed by an external company. Your personal information, such as your name, date of birth and social security number will be shared with this company to put study payments onto the card. While a participant payment card is not a credit card, the company may use your information like a credit card company would. You should review the terms and conditions of the participant payment card when deciding whether to take part in this study. Include if the study enrolls SLU employees ( HYPERLINK "/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/consent_addendum_employee_payment.docx" see optional employee payment form): If you are a Saint ˻ֱ University employee, you have the option of being paid via a participant payment card or the payroll system. You can ask the research staff for more information in order to make a decision about how you want to receive payments. Note: student workers can only receive payment through the payroll system. For payments other than Gift Card payments (i.e., Participant Payment Card/Payroll) include: To receive payment for participation in this study, you will be asked to provide your home address and social security number.If you receive $600 or more for participation in this research study, or a combination of studies at Saint ˻ֱ University in one tax year, you will be sent an IRS Form 1099 for tax purposes. 9. WHAT HAPPENS IF I AM INJURED BECAUSE I TOOK PART IN THIS RESEARCH STUDY? If you believe that you are injured as a result of your participation in the research study, please contact the research study doctor and/or the Chairperson of the Institutional Review Board as stated in section 10. For studies that are more than minimal risk, add the following paragraph. Note: SLU does not generally allow modification to this language/section of the consent. If the study sponsor proposes modifications to this language, please contact the Office of the General Counsel (OGC) at  HYPERLINK "mailto:ogccontracts@slu.edu" ogccontracts@slu.edu to request an exception prior to IRB submission. Please upload the approval correspondence in the Attachments section of the IRB application. You will receive necessary medical treatment in the event that an injury results because of your participation in this research. The University will have the right to determine whether an injury is related to your participation in this study or happened because of your medical condition or other reasons which are not related to this study. If the injury is due to participation in the research, you will not have to pay for the cost of this treatment unless your injury is due to your own failure to follow the study doctors instructions. There are no plans for Saint ˻ֱ University to pay for the costs of any additional care. You have not waived your legal rights by signing this form. If you have questions, please call the Saint ˻ֱ University General Counsel's office at HYPERLINK "tel:314-977-5767" \t "_blank" 314-977-5767. WHO CAN I CALL IF I HAVE QUESTIONS? INSTRUCTIONS: In this section of the consent form, provide the PI or research staff contact information for the participant.  If you have any questions or concerns about this research study, or if you have any problems that occur from taking part in this research study, you may call the researcher (insert name) at (insert PIs phone number). For research studies that are more than minimal risk: include a phone number for after hours. For questions after hours, you may call (list the number) and ask for (insert name). Indicate the name of someone who is on the research team or knows how to contact a member of the research team. If you have questions, concerns or complaints about your rights as a research participant and would like to talk to someone not on the research team, please contact the Saint ˻ֱ University Institutional Review Board (IRB) at 314-977-7744 or  HYPERLINK "mailto:irb@slu.edu" irb@slu.edu. WHAT ARE MY RIGHTS AND WHAT ELSE SHOULD I KNOW AS A RESEARCH STUDY VOLUNTEER? INSTRUCTIONS: This section of the consent form should include the following: The required statement that participation in this research study is voluntary and the participant has the right to withdraw at any time. Disclosure if the researcher may withdraw a subject during the study without the subjects consent when, in the investigators judgment, it is in best interest of the subject to do so under certain circumstances. Required statement for studies that collect biospecimens of the potential use for commercial profit, and whether the subject will share in the commercial profit. Required statement of any financial support on sponsored studies. State any financial disclosures the ˻ֱer(s) may have in relation to the sponsor of this study. If a product of economic value is anticipated to be developed out of the research, disclose whether proceeds will be shared with participants.  Your participation in this research study is voluntary. You may choose not to be a part of this research study. There will be no penalty to you if you choose not to take part. You may leave the research study at any time. The researcher will let you know of any new information that may affect whether you want to continue to take part in the research study. The use of your samples and/or data may result in commercial profit, such as a product, material, or process. You will not be compensated for the use of your samples and/or data other than what is described in this consent form. (This statement may be removed only if no specimens are collected as part of this research). The researcher may take you out of the research study if something happens to make this necessary. (If applicable, please list the potential reasons for early withdrawal of subject participation). If the study is funded outside of the university, include: Saint ˻ֱ University is receiving financial support from [insert sponsor name or funding agency] to assist in the conduct of this research study. The amount of payment is enough to cover the Principal Investigators and/or institutions expenses to perform the research study. 12. AM I SURE THAT I UNDERSTAND? I have read this consent document and have been able to ask questions and state any concerns. The researcher has responded to my questions and concerns. I believe I understand the research study and the potential benefits and risks that are involved. Statement of Consent INSTRUCTIONS: For ˻ֱ Involving participants 7-17 years of age, Use an age appropriate assent information sheet. See Information Sheet templates on the IRB website. For ˻ֱ Involving Participants Whose Ability to Give Consent is in Question/Use of LARs: If a study is being proposed with adults who may be unable to provide consent, this should be described in the IRB Application and LAR signature lines should be retained, below. Please refer to the  HYPERLINK "/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/guidelines_lar.docx" LAR Guidelines for instructions on how to determine who should act as LAR and how to document LAR consent. SIGNATURE INSTRUCTIONS: Delete the signature lines/sections below that are not applicable (LAR/Witness/Assent) Potential signature lines and text to be deleted are in blue. Whenever possible, the IRB stamp should appear on the same page as the participant signature line. A witness signature is required by federal regulations (45 CFR 46.117(b)(2)) with the use of a Short Form consent document, which is most often used in studies that accrue non-English speaking subjects. However, in some cases, the IRB or the ˻ֱer may request the use of a witness signature. The witness line should be signed by an individual who witnesses the research participant sign and date the consent form document. This signature can be a family member, friend, etc. The witness signature should not reflect the signature of the person responsible for obtaining informed consent. The Principal Investigator or ˻ֱ Team Member that signs the consent form must be authorized in the protocol to obtain informed consent and must sign at the SAME time as the participant signature is obtained. Use the following lines for adult participants or remove. (minors section is below) I give my informed and voluntary consent to take part in this research study. I will be given a copy of this consent document for my records. _____________________________________ Print Name of Participant _____________________________________ ________________ Consent Signature of ˻ֱ Participant (18 and over) Date Use the following lines if an LAR signature is needed or remove. (minors section is below) I give my informed and voluntary consent for the person I represent to take part in this research study. I will be given a copy of this consent document for my records. _____________________________________ Print Name of Participant _____________________________________ Print Name of Guardian/Legal Representative _____________________________________ ________________ Signature of Guardian/Legal Representative Date _____________________________________ Description of Relationship to Participant Use the following lines if a witness signature is needed or remove. Note: the witness should be someone unrelated to the research; a subject relative would qualify. _____________________________________ Print Name of Witness _____________________________________ ________________ Signature of Witness Date Use the following section for research involving minors or remove. Include the text from ASSENT SECTION down to the IRB approval stamp box ONLY if the study requires obtaining minors assent. I have read this consent document and agree to allow my child to be in this research study with the understanding that I may withdraw him/her at any time. If my child is 7 years of age or older, this research study has been explained to him/her and he/she agrees to participate. I will be given a copy of this consent document for my records. _____________________________________ Print Name of Participant _____________________________________ Print Name of Parent/Guardian/Legal Representative _____________________________________ ________________ Signature of Parent/Guardian/Legal Representative Date _____________________________________ Description of Relationship to Participant ASSENT SECTION: Statement of Parent, Guardian, or Legal Representative: My child appears to understand the research to the best of his or her ability and has agreed to participate. _____________________________________ ________________ Signature of Parent/Guardian/Legal Representative Date SAINT LOUIS UNIVERSITY INSTITUTIONAL REVIEW BOARD APPROVAL STAMP This form is valid only if the IRBs approval stamp is shown below.  I certify that I have explained to the above individual(s) the nature and purpose of the research study and the possible benefit and risks associated with participation. I have answered any questions that have been raised and the participant has received a copy of this signed consent document. If this study involves participants who are minors: I have explained all aspects of the research to the minor to the best of his or her ability to understand. I have answered all the questions of the minor relating to this research. The minor agrees to be in the research. I believe the minors decision to enroll is voluntary. The Principal Investigator and study staff agree to respect the minors physical or emotional dissent at any time during this research when that dissent pertains to anything being done solely for the purpose of this research. Signature of Consenting ˻ֱ Team MemberDate First Name / Last Name CredentialsPrinted Name of Consenting ˻ֱ Team Member NOTE: The Principal Investigator or ˻ֱ Team Member that signs here must be authorized in the IRB approved protocol to obtain informed consent and should sign at the SAME time the above signatures are being obtained. In school-based or similar research, the IRB often approves a consent process whereby participant consent is obtained and documented outside of the presence of a researcher. In these cases, the PI/˻ֱ team member can sign and date the form once received from the participant. DO NOT SUBMIT THE FOLLOWING SECTION/PAGES TO THE IRB ADDITIONAL INSTRUCTIONS/SAMPLES OF CONSENT FORM LANGUAGE Please note: for the following pages, italicized and/or underlined text are instructions. Bulleted text is sample language that can be modified to fit your study and cut/pasted into the consent form document if applicable. INTRODUCTION: Examples of text for the Introduction paragraph: Review the introduction paragraph of the consent document. Modify any of the statements below to complete the introduction paragraph of the consent form for your research study. The statements below can be cut and pasted into your consent form document. You are being asked to take part in this research study because you are fill in unique reason (e.g., a parent of an internationally-adopted child). You may take home an unsigned copy of this consent document in order to think about this research study before making your decision. Note, if you are not targeting a specific population for your research study, you can state, You are being asked to take part in a research study conducted by name of principal investigator and colleagues.  HYPERLINK \l "INTRO" Back to Consent Document PURPOSE: Additional instructions for the WHY IS THIS RESEARCH STUDY BEING DONE? section: Studies involving Deception If the researcher is using deception (misleading communication about the purpose of the research and/or the procedures employed in the research), please follow these guidelines for the consent document: Do NOT include any information that is untrue in the consent form. The consent form should not be part of the deception. Include as many details as possible regarding research study procedures without invalidating the integrity of the research. Include all significant aspects that would affect an individuals willingness to participate (physical risks, discomforts, unpleasant emotional experiences, etc). NOTE: ˻ֱers must discuss the full details of the research study to participants at the earliest point possible, preferably at the conclusion of the participants role in the study, but no later than at the conclusion of the research study at large. Any waiver of this debriefing requirement will require IRB approval.  HYPERLINK \l "PUR" Back to Consent Document  PARTICIPATION: Examples of text for the WHAT AM I BEING ASKED TO DO? section: Participating in Other ˻ֱ Studies It is important that you tell the researcher if you have been in another research study in the past year or are currently in another research study. There are reasons such as fill in with relevant examples (e.g. potential conflict/bias from participating in previous research study) that will let the researcher know if you can take part in this research study. -OR- You may not be in another fill in type of study research study while you are in this research study.  HYPERLINK \l "Section2" Back to Consent Document  Screening Procedures If participants will be asked questions about medical history or personal life, etc. to determine eligibility for the research study, this should be stated. Basic inclusion or exclusion criteria may be listed in the consent document; however, if there are several research study entry criteria, it would be more appropriate to provide a detailed list to the potential participant on a separate sheet. You will be asked questions about your medical history/personal life to help the researcher decide if you can take part in this research study. You cannot take part if(list reasons).  HYPERLINK \l "Section2" Back to Consent Document  Follow-up Visits You will need to return to (research site) every (state the frequency) for (state the duration). (State the research study procedures and how often they will be performed). Note: When a participant withdraws from a research study before completion of participation, it is sometimes desirable to have a final follow-up visit. The researcher may encourage the participant to do so; however, the participant may choose to withdraw without returning for a final follow-up visit. Include appropriate language in the consent document.  HYPERLINK \l "Section2" Back to Consent Document  Interviews/Questionnaires Describe the procedures related to the interview/questionnaires. Give examples of the nature of the questions (e.g., social, occupational, sexual, domestic, and other behaviors). Below are two examples; you may modify the text to describe your study. In this research study, you will be asked to take part in an interview. The interview will take place in a private room at Saint ˻ֱ University. You will be asked about your eating and exercise habits, and how often you smoke and/or drink alcohol. The interview will last about one hour. In this research study, you will be asked to complete several questionnaires. You will be asked about your eating and exercise habits, and how often you smoke and/or drink alcohol.  HYPERLINK \l "Section2" Back to the Consent Document  ˻ֱ Involving photographs/audiotapes/videotapes Using the following language as a guide, describe the recording being done, including whether images will be retained or destroyed. Signature lines can be added to this section if being recorded is optional. As part of the research study, the researcher willrecord your [image and/or voice] in a [videotape/audio recording/photograph].The [recording/photo] may be used in a presentation or publication about this research study. The use of the [recording/photograph] may include news releases, professional conferences, websites and exhibits related to this research study. Also, the [recording/photograph] may be kept for future research studies or educational purposes.[Alternatively, if not retaining the video/audio tape: After the researcher has taken notes from the recording, it will be destroyed to protect your identity.] The [recording/photograph] will include [a picture of your face/sound of your voice], but the researcher will not reveal your name or other identifying information.  HYPERLINK \l "Section2" Back to the Consent Document  Future recruitment for research studies May a member of the research team contact you to invite your participation in future research studies? ____Yes ____No  HYPERLINK \l "Section2" Back to the Consent Document  Future Use of Data or Specimens When subjects agree to participate in research, they must be informed of whether or not data/specimens will be collected and stored for future research use. FUTURE USE OF SAMPLES OR DATA FOR FUTURE RESEARCH MUST include one of the following statements if the research study involves the collection of identifiable data or identifiable biospecimens: Identifiers might be removed from your data and/or samples collected in this research, and used for future research studies or distributed to other researchers for future research studies with/without your additional permission. -OR- Your data and/or samples collected as part of this research, even if identifiers are removed, will not be used or distributed for future research studies. If future use is anticipated, please include the following text as appropriate for your study. Modify the text within the box to fit your research study. Remember the italicized text is instructional. You may delete sections if they do not apply to your research study. Description of specific future use or broad use if will be used for unspecified future research Future studies may provide additional information that will be helpful in understanding (describe the area of future research OR state that you are keeping the samples/data for any type of future research). It is likely that what we learn from the future research will have no direct benefit to you. Description of confidentiality measures If coded: Samples/data will be kept with coding, meaning that all direct identifiers like your name will be removed from the sample and/or data and replaced with a research number. A listing of your name and associated research number will be kept separately for privacy protection. -OR- If anonymous: All information that identifies you will be removed from your samples/data to be used for future research. How will my samples and/or data be shared? The researchers may share your samples/data with other people doing research at SLU or other research centers. Other researchers will not have access to your name or other identifying information. Potential to develop a product with economic value In this research study, a valuable product, material, or process (such as a book, new drug, or new cell line) may be developed. A cell line is a family of cells grown in a laboratory. Cell lines used for research sometimes result in the development of new products. Should a product be developed, there are no present plans to share any monies obtained from the sale of the product with you, and you give up ownership of the samples/data. Withdrawing future use specimens If you choose to withdraw your samples/data in the future, you can contact the researcher at the number provided in this consent document. Your samples/data will be removed for any future uses, but we cannot remove them from studies that were already conducted. OR if anonymous: Because your name will not be associated with the samples/data to be used in the future, we will not be able to remove them should you change your mind in the future. Sample Language to Capture Decision about Participating in Optional Future ˻ֱ Use: This section can be revised to include tiered options (like only allowing certain kinds of research) Please write your initials by the statement you agree with, below: ___ I do want to take part in the future research use of my samples/data. ___ I do not want to take part in the future research use of my samples/data.  HYPERLINK \l "Section2" Back to the Consent Document RISKS: Examples of text for the WHAT ARE THE RISKS? section: Include any of the following statements as appropriate Interviews/Questionnaires Some questions in the (interview or questionnaires) may make you feel uncomfortable. You do not have to answer questions that make you uncomfortable. Indicate whether the responses to the research questions will be coded to protect confidentiality. The survey you are given is coded so that we will know when you return the survey to us without having to put your name on the survey. When all of the surveys have been returned, the list with names and numbers will be destroyed.  HYPERLINK \l "RIS" Back to the Consent Document Breach of Confidentiality when ˻ֱ Involves Sensitive Issues Please modify as necessary Taking part in this research study, if it became known outside the research, could place you at risk with the law, harm your reputation, or hurt your ability to keep your job or get a new one. It also may hurt your ability to have insurance (health, life, auto, etc). Every effort will be made to protect your research study data. There is, however, always the possibility of a breach of confidentiality.  HYPERLINK \l "RIS" Back to the Consent Document Breach of Confidentiality when ˻ֱ Involves Sensitive Issues Requiring a Certificate of Confidentiality Please modify as necessary Taking part in this research study, if it became known outside the research study, could place you at risk with the law, harm your reputation, or hurt your ability to keep your job or get a new one. It also may hurt your ability to have insurance (health, life, auto, etc). Although there is always the possibility of a breach of confidentiality, every effort will be made to protect your research data. The researcher has obtained a Certificate of Confidentiality from a government agency to further protect your data. This Certificate is explained in detail in section #7, Will My Information Be Kept Private?  HYPERLINK \l "RIS" Back to the Consent Document BENEFITS: Examples of text for the ARE THERE BENEFITS TO BEING IN THIS RESEARCH STUDY? section: Benefit example Please modify the statement to fit your study In this research study, your child will complete tasks that show how they rank compared to other children mentally and physically. The researcher will share with you how well your child did on those tasks.  HYPERLINK \l "Section5" Back to the Consent Document CONFIDENTIALITY AND PRIVACY: Examples of text for the WILL MY INFORMATION BE KEPT PRIVATE? section: ˻ֱ Records Containing Identifiers Your research study record will contain some of your personal information, such as (give examples, such as date of birth, social security number, etc). The researcher will keep your research record protected by (list the protections detailed in the protocol).  HYPERLINK \l "CONF" Back to the Consent Document  Data Sharing Information collected for this research study may be shared with other researchers. If this information about you (your child/adolescent) is shared, it will not include names, addresses, or other identifying information.  HYPERLINK \l "CONF" Back to the Consent Document  Release of Individual ˻ֱ Results If you ask for the result of the research-related health tests before finishing the research study, and share this information with your primary care physician, he/she may intervene (e.g., put you on treatment). If this happens, you may be withdrawn from the research study. -OR- In the course of this study, doctors may find out information about your health that was unplanned. Doctors do not plan to give you this information. -OR- In the course of this study, doctors may find out information about your health that was unplanned. If this information is valid, can impact your health and can be treated, you will be told. Otherwise, doctors do not plan to give you this information. -OR- In the course of this study, doctors may find out information about your health that was unplanned. Doctors are willing to tell you information that is valid, can impact your health and can be treated. Please indicate below if you want to receive this information: ___ I want to be told about medical information. ___ I do not want to be told about medical information.  HYPERLINK \l "CONF" Back to the Consent Document  Mandated Reporter/Reporting If the study involves mandatory reporting, use the following language. Child can be replaced by elder. Under State law, we cannot keep information about known or reasonably suspected abuse or neglect of a child confidential, including but not limited to physical, sexual, emotional abuse or neglect. If any member of the study team has or is given such information, he or she is required to report it to the appropriate authorities  HYPERLINK \l "CONF" Back to the Consent Document  MUST include if this is NIH funded research or any other research with a Certificate of Confidentiality: For studies that have been issued a Certificate of Confidentiality, NIH has specific criteria for disclosure to participants, per the  HYPERLINK "https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html" NIH Policy for Issuing Certificates of Confidentiality. Studies that involve collection or use of identifiable sensitive information may have a Certificate of Confidentiality through NIH either because: A Certificate of Confidentiality was automatically issued with the terms and conditions of the award (only studies funded on or after December 2016) OR- The research team has applied for and obtained a Certificate of Confidentiality from NIH. NIH expects researchers to tell participants about the protections afforded by the Certificate of Confidentiality. NIH provides the sample language below which should be adapted to the study participants and subject matter of the research and included in the confidentiality section of the informed consent document: Certificate of Confidentiality This research is covered by a Certificate of Confidentiality from the National Institutes of Health. The researchers with this Certificate may not disclose or use information, documents, or biospecimens that may identify you in any federal, state, or local civil, criminal, administrative, legislative, or other action, suit, or proceeding, or be used as evidence, for example, if there is a court subpoena, unless you have consented for this use. Information, documents, or biospecimens protected by this Certificate cannot be disclosed to anyone else who is not connected with the research except, if there is a federal, state, or local law that requires disclosure (such as to report child abuse or communicable diseases but not for federal, state, or local civil, criminal, administrative, legislative, or other proceedings, see below); if you have consented to the disclosure, including for your medical treatment; or if it is used for other scientific research, as allowed by federal regulations protecting research subjects. [Use the following language as applicable] The Certificate cannot be used to refuse a request for information from personnel of the United States federal or state government agency sponsoring the project that is needed for auditing or program evaluation by [THE AGENCY] which is funding this project or for information that must be disclosed in order to meet the requirements of the federal Food and Drug Administration (FDA). You should understand that a Certificate of Confidentiality does not prevent you from voluntarily releasing information about yourself or your involvement in this research. If you want your research information released to an insurer, medical care provider, or any other person not connected with the research, you must provide consent to allow the researchers to release it. [language such as the following should be included if researcher intends to disclose information covered by a Certificate, such as potential child abuse, or intent to hurt self or others in response to specific federal, state, or local laws.] The Certificate of Confidentiality will not be used to prevent disclosure as required by federal, state, or local law of [list what will be reported, such as child abuse and neglect, or harm to self or others]. [language such as the following should be included if researcher intends to disclose information covered by a Certificate, with the consent of research participants.] The Certificate of Confidentiality will not be used to prevent disclosure for any purpose you have consented to in this informed consent document [restate what will be disclosed, such as including research data in the medical record].  HYPERLINK \l "CONF" Back to the Consent Document COSTS AND PAYMENTS: Examples of text for the WHAT ARE THE COSTS AND PAYMENTS? section: Include mention of any payment to participants (e.g., for time and travel). For research involving more than one interaction, payment must be prorated. ˻ֱer/Sponsor Covers All Costs There will be no additional costs to you for taking part in this research study. All research study procedures including (insert detail if necessary) are provided to you by the researcher (or insert sponsor name if applicable). Payment You will be paid (insert total amount) for taking part in this research study if you complete the study. If you do not complete this research study, you will be paid (insert amount). Explain with specificity the method of prorating the payment(s).  HYPERLINK \l "COSTS" Back to the Consent Document  VOLUNTARY PARTICIPATION: Examples of text for WHAT ARE MY RIGHTS AS A RESEARCH STUDY VOLUNTEER? section: The researcher may withdraw you from this research study without your consent when, in the researchers judgment, it is in your interest to do so, or under certain circumstances, such as (list relevant examples): Possible examples of circumstances when termination may occur are: Discomforts occur that may place you at risk of further complications if participation is continued, Inability to participate as instructed, Inability to keep scheduled appointments, Cancellation by the study sponsor or regulatory agency HYPERLINK \l "Rights"Back to the Consent Document     IRB Template Date: 10/2019 PAGE  PAGE 8 Version Date: IRB Template Date: 10/2019 13OTU^_xz 5 6 7 񪝪n`Jn*jh['h5OJQJU^Jh['h5OJQJ^J$jh['h5OJQJU^Jh['h#s5OJQJ^Jh['h2y"5OJQJ^Jh['h&OJQJ^Jh['hXOJQJ^Jh['hX5>*OJQJ^Jh['hX/T5OJQJ^Jh['hm5OJQJ^Jh['hDm5OJQJ^Jh['hX5OJQJ^J23yz R S n { & F ^gd.B8^8gdX & F 85$7$8$9DH$`gd.B 5$7$8$9DH$gd y^gd#sl  5$7$8$9DH$gd2y" & F 8L5$7$8$9DH$^`Lgd.B$a$gdX 7 O P Q R S Y  &  =ikmoreWJh['h7UOJQJ^Jh['h},5OJQJ^Jh['heOJQJ^Jh['hOJQJ^Jh['h2gOJQJ^Jh['hpOJQJ^Jh['hXOJQJ^Jh['hX5OJQJ^Jh['h yOJQJ^Jh['h#sOJQJ^Jh['h`m65OJQJ^J$jh['h5OJQJU^Jh['h#s0J5OJQJ^Jn o ijk9:tv & F 5$7$8$9DH$^gd.B8^8gdX^gdX^gdX & F 8L5$7$8$9DH$^`Lgd.B & F ^gdegdh^hgdX & F ^gd.B^gdX %AHJ^`Ns-d:&)/15BDGijz{ƹwjh['h]OJQJ^Jh['hKOJQJ^Jh['hMOJQJ^Jh['h/OJQJ^Jh['hpOJQJ^Jh['hX5OJQJ^Jh['hXOJQJ^Jht/hXOJQJ^Jh['hX>*H*OJQJ^Jh['h>*OJQJ^Jh['hX>*OJQJ^J&tuef 5$7$8$9DH$gd y 5$7$8$9DH$gd#J & F 5$7$8$9DH$^gd.Bh5$7$8$9DH$^hgdX 5$7$8$9DH$gdX & F 5$7$8$9DH$^gd.BgdX  ^ q{˾{naTanDh['h*95>*OJQJ^Jh['hVw!OJQJ^Jh['hz:iOJQJ^Jh['h*9OJQJ^Jh['h>HOJQJ^Jh['h]OJQJ^Jh['h@7OJQJ^Jh['h/5OJQJ^Jh['h7m5OJQJ^Jh['hPOJQJ^Jh['h"OJQJ^Jh['h yOJQJ^J *h['h#JOJQJ^Jh['hOJQJ^J{8ix#FO࢕{n{`RDR{h['h..5OJQJ^Jh['hVw!5OJQJ^Jh['h y5OJQJ^Jh['hOJQJ^Jh['hVw!OJQJ^Jh['h\OJQJ^Jh['h>HOJQJ^Jh['h*95OJQJ^Jh['h y5>*OJQJ^Jh['hVw!5>*OJQJ^Jh['h5>*OJQJ^Jh['h*95>*OJQJ^Jh['hwS5>*OJQJ^JH^Y$a$~kd$$Ifl      '8(  t 0      644 l` ap ytw7 & F $Ifgde & F $Ifgdw7 $Ifgd/ OS\bqGH $;<XYZ濲٘يzjz[I8z h['hX/TCJ OJQJ^JaJ #h['hX/T5CJ OJQJ^JaJ h['hX/TCJOJQJ^Jh['h]5CJOJQJ^Jh['hX/T5CJOJQJ^Jh['h/5OJQJ^Jh['h yOJQJ^Jh['hz:iOJQJ^Jh['hIHYOJQJ^Jh['h?pOJQJ^Jh['heOJQJ^Jh['hVw!OJQJ^Jh['h\OJQJ^Jh['hSOJQJ^J!"#$;<YZ[j$x$If]xa$gdX/T $$Ifa$gdX/TgdX/T$a$gdX/T Z[agijk~'79;DKŵŧӃo^oIoIoIoIoIoIo^)h['hX/T5>*CJOJQJ\^JaJ h['hX/TCJOJQJ^JaJ&h['hX/T5CJOJQJ\^JaJ&h['h5CJOJQJ\^JaJh['h5OJQJ\^Jh['hOJQJ]^Jh['hX/T6OJQJ]^Jh['hX/TOJQJ]^Jh['hX/T5OJQJ\^Jh['h 5OJQJ\^Jh['hX/TOJQJ^J~~~~yNy*$d %d &d 'd N O P Q ^gdgdX/T$a$gdX/TykdJ$$Ifl40'0'64 lalf4yt['9h'JhABClm$a$$a$gdX/T $ & F h5$7$8$9DH$^`a$gdX/T $ & F 8h5$7$8$9DH$^`a$gdX/TgdX/TCjklmnopƲƢsaRB2%h['hpOJQJ^Jh['hp5CJOJQJ^Jh['h6CJOJQJ^Jh['hCJOJQJ^J#h['hA5CJOJQJ^JaJh['hScCJOJQJ^Jh['hg0 5CJOJQJ^Jh['hX/T5CJOJQJ^Jh['hSc5CJOJQJ^J&hhX/T5CJOJQJ\^JaJ)h['hX/T5>*CJOJQJ\^JaJ h['hX/TCJOJQJ^JaJ&h['hX/T5CJOJQJ\^JaJmop $IfgdFm$ !$IfgdFm$gdp$a$gdgO$a$gdg0 -.01kVkkE h['hpCJOJQJ^JaJ) *h['hp6CJOJQJ\^JaJ&h['hp5CJOJQJ\^JaJ*h['hp5CJOJQJ\^JmH sH "h['hp6CJOJQJ\^J)h['hp6CJH*OJQJ\^JaJh['hpCJOJQJ^J%h['hp56CJOJQJ\^Jh['hpCJOJQJ\^J"h['hp5CJOJQJ\^J=.# $IfgdFm$ !$IfgdFm$kd$$If\ dX '  0'4 apytFE66 !$IfgdFm$kd$$IfF d'  0'    4 apytF $IfgdFm$2kd$$IfU\ dX '  0'4 apytF $IfgdFm$./0PEEE $IfgdFm$kd$$IfF d'   0'    4 apytF0123i ytn```  !$Ifgdw7 !gdkd$$If0 ' L  0'4 ap ytF123@himov: ; Y ̵lLl>jh['hLB*OJQJU^JaJmH nH phsH tH 5h['hLB*OJQJ^JaJmH nH phsH tH ,h['hz:iOJQJ^JaJmH nH sH tH ,h['hi3OJQJ^JaJmH nH sH tH ,h['hOJQJ^JaJmH nH sH tH /h['h5OJQJ^JaJmH nH sH tH h['hScCJOJQJ^Jh['hOJQJ^JY Z [ g h i j k  ݽ|m^O^@^1h['h<CJOJQJ^Jh['hCJOJQJ^Jh['hLCJOJQJ^Jh['hScCJOJQJ^Jh['hCJOJQJ^Jh['hOJQJ^J5h['hz:iB*OJQJ^JaJmH nH phsH tH 0h['hL0JOJQJ^JaJmH nH sH tH >jh['hLB*OJQJU^JaJmH nH phsH tH Djh['hxB*OJQJU^JaJmH nH phsH tH  i j k !!n"o"j#k#~xoxxdbbYY $Ifgd{  !5$9DH$ $ !a$ !kdD$$Ifl      `'`'  t 0      644 l` alp yt !!!%!}!!!!!!!!!!!/"3"ﱒp[F[1(h['h<5OJQJ\^J(h['hSc5OJQJ\^J zf(h['hSc5OJQJ\^Jh['hScOJQJ^JaJ%h['hScB* CJOJQJ^Jphhh fCJOJQJ^Jh['h..>*CJOJQJ^Jh['h f>*䴳ϴ'󳧳䴳ϴ󳧳䴳ϴ'󳧳>*䴳ϴ'<>*䴳ϴ3"=">""""""""""1#7#;#<#=#U#g#j#wj`jVL`j?`V`h&CHhcNOJQJ^JhE#OJQJ^Jh OJQJ^JhcNOJQJ^Jh1RhcNOJQJ^Jh`hcN5OJQJ^J(h['hcN5OJQJ\^J"hSc5OJQJ\^J(h['hH5OJQJ\^J(h['hSc5OJQJ\^J(h['h<5OJQJ\^J(h['h:E5OJQJ\^Jj#k#n########$$X%%%%%%%%w&x&y&}&~&&俲䤙{p]{M{hhcN0JOJQJ]^J$jhOJQJU]^JhOJQJ]^JjhOJQJU]^JhEjHhcNOJQJ]^JhcNOJQJ]^Jh hcNOJQJ]^JhhcNOJQJ^Jh1RhcN>*OJQJ^Jh:hcNOJQJ^JhcNOJQJ^Jh1RhcNOJQJ^Jh1RhcN5OJQJ^Jk#&&&&&&5'|zm]C & F$5$7$8$9DH$IfgdcNm$$ m $Ifa$gd{ m $Ifgd{zkd $$Ifl      ''  t 0      644 lalp yt{ $Ifgd{&&&&&&&&&2'5'>'q'''''''''2(((ȴȢ|gXggG h6:hcNCJOJQJ^JaJhcN5CJOJQJ^JaJ)hmhcNB*CJOJQJ^JaJph)hhcNB*CJOJQJ^JaJph h1RhcNCJOJQJ^JaJ#h1RhcN5CJOJQJ^JaJ&h1RhcN5>*CJOJQJ^JaJhcN5OJQJ^Jh:hcN5OJQJ^J"h"5OJQJ\^Jh1RhcN6CJaJ5'''()****ZXqkdH $$Ifl'' t0644 lalp yt{ h$If^hgd{ & F$IfgdcN & F$5$7$8$9DH$IfgdcNm$(((|)))))))*****ǶtccXJ<h`hcN5OJQJ^JhAhcNOJQJ]^JhcNOJQJ]^J h1RhcNCJOJQJ^JaJhcNCJOJQJ^JaJ h%hcNCJOJQJ^JaJ hahcNCJOJQJ^JaJ#h)jchcN5CJOJQJ^JaJ h)jchcNCJOJQJ^JaJ)hmhcNB*CJOJQJ^JaJph hnhcNCJOJQJ^JaJ#hnhcN5CJOJQJ^JaJ****++++!+F+O+U+V+^+e+m+t+{++++++*,0,@,A,b,˻˫tggZgZgMgMgtgh['hSOJQJ^Jh['hCOJQJ^Jh['h*kOJQJ^Jh['hKOJQJ^Jh['hOJQJ^Jh['h*k5OJQJ^Jh['h9CJOJQJ^Jh['h95CJOJQJ^Jh['h'5CJOJQJ^Jh['htv5CJOJQJ^Jh['hSc5OJQJ\^J(h['hcN5OJQJ\^J*++h++@,{-|-- $Ifgd i $Ifgd`} & F$Ifgdw7 & F$Ifgdw7 $Ifgd*kgd8` & F h0`0gd.Bb,k,,,,,,,'-)-*---.-2-3-Y-Z-j-n-y-z-|--------濲椑~k~k~X$h['hz B*OJQJ]^Jph$h['h3B*OJQJ]^Jph$h['hMTB*OJQJ]^Jph$h['h`}B*OJQJ]^Jphh['h`}OJQJ]^Jh['h(OJQJ^Jh['hKOJQJ^Jh['h6OJQJ^Jh['hoKkOJQJ^Jh['h*kOJQJ^Jh['hu1OJQJ^J------------....|m]M?/h['h95OJQJ]^Jh['h9OJQJ\^Jh['hSc5OJQJ\^Jh['htv5OJQJ^JaJh['hScCJOJQJ^Jh['h*k5OJQJ^Jh['hCOJQJ\^J$h['h3B*OJQJ\^Jphh['h3OJQJ\^Jh['h i0JOJQJ\^J*j h['h iOJQJU\^Jh['h iOJQJ\^J$jh['h iOJQJU\^J---....V012vh__RRR & F$Ifgdw7 $Ifgd9 5$9DH$^gd8`  & F5$9DH$gdXzkdI $$Ifl      `'`'  t 0      644 lalp yt .8.A.G.O.Q.X.].l.m....../s//6090T0U0V0f0n0x0y0~00000001%131B1񁏝ǏǏǏsesh['h]OJQJ]^Jh['hTOJQJ]^Jh['hkOJQJ]^Jh['h,} OJQJ]^Jh['hLh.OJQJ]^Jh['h>OJQJ]^Jh['hcXIOJQJ]^Jh['h9OJQJ]^Jh['h)iOJQJ]^Jh['h JOJQJ]^Jh['hOJQJ]^J%B1J11111112222223333=3U3Y3p3q3'4(4ǹvvvvi[Mh['h>OJQJ]^Jh['hOJQJ]^Jh['h(OJQJ^Jh['h?@OJQJ]^Jh['h(OJQJ]^JhcXIOJQJ]^Jh['hOJQJ]^Jh['h]OJQJ]^Jh['hcXIOJQJ]^Jh['h9OJQJ]^Jh['h JOJQJ]^Jh['hTOJQJ]^Jh['h=JOJQJ]^J22q3'4(444[5555,6 & F$Ifgdw7 $IfgdO* $Ifgd> & F$Ifgdw7 & F $If^`gdw7 (4,434M4]4h4i4n4u4w4444444444445ǴڴjZLh['h6tOJQJ]^Jh['h6t0JOJQJ\^J*j h['h6tOJQJU\^Jh['h6tOJQJ\^J$jh['h6tOJQJU\^J$h['h_4B*OJQJ]^Jph$h['hO*B*OJQJ]^Jph$h['hgB*OJQJ]^Jph$h['hCB*OJQJ]^Jph$h['h>B*OJQJ]^Jph555,5-5.5/5W5X5Y5Z5[5\5v5w5x5~55555׹t׹^N@h['h6tOJQJ]^Jh['h J0JOJQJ\^J*jh['h6tOJQJU\^Jh['h=yOJQJ]^J*j h['hxOJQJU\^Jh['h_OJQJ\^J$jh['h_OJQJU\^Jh['h6tOJQJ\^Jh['h6t0JOJQJ\^J$jh['h6tOJQJU\^J*j h['h6tOJQJU\^J555555555555556̾wgYF8h['h*I OJQJ\^J$jh['h*I OJQJU\^Jh['h(OJQJ\^Jh['h(0JOJQJ]^Jh['h(0JOJQJ\^J*j h['h 5OJQJU\^Jh['h~OJQJ\^J$jh['h~OJQJU\^Jh['hhOJQJ\^J$jh['h_OJQJU\^Jh['h_0JOJQJ\^Jh['h=y0JOJQJ\^J666*6+6,6-6.66666666׹n\M;';&h[h>*CJOJQJ]^JaJ#hhCJOJQJ]^JaJhCJOJQJ]^JaJ#h[hCJOJQJ]^JaJ#h[hvCJOJQJ]^JaJ,h@$h56>*CJOJQJ\^JaJ&h56>*CJOJQJ\^JaJh['h9OJQJ\^Jh['h*I OJQJ]^Jh['h*I 0JOJQJ\^J$jh['h*I OJQJU\^J*jh['h*I OJQJU\^J,6-6.6667C8D8n8o88vvqid[ $Ifgdkgd8` & FgdX gd/ & F gdm$gdzkd$$Ifl      `'`'  t 0      644 lalp yt 6|7777777C8D8E8G8^8g8m8n8~jVjBj.&h['hSc5CJOJQJ\^JaJ&h['h'5CJOJQJ\^JaJ&h['h3l5CJOJQJ\^JaJ&h['htv5CJOJQJ\^JaJ h['hg0 CJOJQJ^JaJ#hhCJOJQJ\^JaJ&h[h>*CJOJQJ\^JaJ#h[hCJOJQJ\^JaJ#hhCJOJQJ]^JaJ&h[h>*CJOJQJ]^JaJ#h[hCJOJQJ]^JaJn8o8}8$979B9C9E9F999999999999ŷӷӜ~o`Q`Bh['h_CJOJQJ^Jh['h2gCJOJQJ^Jh['h)iCJOJQJ^Jh['h>HCJOJQJ^Jh['hSc>*CJOJQJ^Jh['hk>*OJQJ^Jh['hkOJQJ^Jh['h%OJQJ]^Jh['hg0 OJQJ]^Jh['hb^OJQJ]^Jh['hkOJQJ]^Jh['hk5OJQJ]^Jh['hkCJOJQJ^J8F99999999 : :xvqqqqi_ 5$9DH$gd8` & FgdX gd"zkd$$Ifl      `'`'  t 0      644 lalp yt & F$Ifgdw7 99999: : :::@:A:B:L:t;;;;;yi[M[?[1[1[h['hSOJQJ]^Jh['hX OJQJ]^Jh['h%OJQJ]^Jh['hJ;OJQJ]^Jh['hJ;5OJQJ]^Jh['hg0 5OJQJ]^J h['hg0 CJOJQJ^JaJ&h['hX 5CJOJQJ\^JaJ#h['hX 5CJOJQJ^JaJ h['hCJOJQJ^JaJ h['hvtCJOJQJ^JaJh['hvtCJOJQJ^Jh['hScCJOJQJ^J :8;9;,<<<<7=o==1> & F$Ifgdw7 $Ifgdg & F$5$9DH$Ifgdw7$5$9DH$Ifgdw7 ;+<,<.<<<<<<<<<<==7=8=S=T=U=չիn[An3j3h['h{NB*OJQJU]^Jph$h['h{NB*OJQJ]^Jph-jh['h{NB*OJQJU]^Jph$h['h%B*OJQJ]^Jph$h['hgB*OJQJ]^Jphh['h)iOJQJ]^Jh['h8OJQJ]^Jh['h%OJQJ]^Jh['huA(OJQJ]^Jh['hJ;OJQJ]^Jh['hb OJQJ]^JU=o=p=q============/>0>taJ0JJ3jh['h,MB*OJQJU]^Jph-jh['hB*OJQJU]^Jph$h['hgB*OJQJ]^Jphh['h=y0JOJQJ]^Jh['hg0JOJQJ]^J3jh['h,MB*OJQJU]^Jph$h['hB*OJQJ]^Jph-jh['hGB*OJQJU]^Jph-jh['h{NB*OJQJU]^Jphh['h{N0JOJQJ]^J0>1>2>3>d>>>>>>>>>>>>>ʹxgVgE3#h['h f6CJOJQJ^JaJ h['h:ECJOJQJ^JaJ h['hK 5CJOJQJ^JaJ h['h fCJOJQJ^JaJh['hScOJQJ^J#h['h[N6CJOJQJ^JaJ h['h?CJOJQJ^JaJ h['h\eCJOJQJ^JaJ h['hScCJOJQJ^JaJ h['hg0 CJOJQJ^JaJ#h['hg0 5CJOJQJ^JaJ$h['hg0 B*OJQJ]^Jph1>2>3>>>>>G?H?@@A@@@{yyyyytttyygd 5$9DH$gdg0 zkd$$Ifl      `'`'  t 0      644 lalp yt >>>>>??????(?*?+?8?*CJOJQJ^JaJ h['h:ECJOJQJ^JaJ h['hScCJOJQJ^JaJ h['h fCJOJQJ^JaJ#h['h f6CJOJQJ^JaJ&h['hq6>*CJOJQJ^JaJ&h['h f6>*CJOJQJ^JaJH?@@A@E@M@O@P@Q@@@@@@@@@@пСzhVhD3 h['huA(CJOJQJ^JaJ#h['hSc5CJOJQJ^JaJ#h['h'5CJOJQJ^JaJ#h['htv5CJOJQJ^JaJ#h['hX 5CJOJQJ^JaJ)h['hB* CJOJQJ^JaJphh['hScOJQJ^J h['h:ECJOJQJ^JaJ h['h/mCJOJQJ^JaJ h['hScCJOJQJ^JaJ h['h:HkCJOJQJ^JaJh:HkCJOJQJ^JaJ@@@AAhBiBBBBBLCkfdgduA(kd$$Ifl      `'`'  t 0      644 l` alp yt $IfgduA(gd8`gdX @@AAAA-BLBMBeBiBBBBBBBBBB♈u^uD^4^h['hh0JOJQJ]^J3j4h['hxB*OJQJU]^Jph-jh['hhB*OJQJU]^Jph$h['hhB*OJQJ]^Jph!h['h6+nB*OJQJ^Jph!h['hhB*OJQJ^Jphh['hb^OJQJ]^Jh['hDTOJQJ]^Jh['h`c OJQJ]^Jh['hvtOJQJ]^Jh['huA(OJQJ]^Jh['huA(5OJQJ]^JBBBBBBBCC*CGCKCLCzC{CCCCDDDοrrcScrDr5h['h\eOJQJ^JaJh['hLbOJQJ^JaJh['ht>*OJQJ^JaJhhtOJQJ^JaJh['hHOJQJ^JaJh['hScOJQJ^JaJh['h$>*OJQJ^JaJh['huA(>*OJQJ^JaJhhOJQJ^JaJh['huA(OJQJ^JaJ h['hScCJOJQJ^JaJh['huA(5OJQJ^J$h['huA(B*OJQJ]^JphLCMCDD*D+DzDD-E.ESkdR$$Ifl      `'`'  t 0      644 l` alp yt & F$Ifgdw7 $IfgduA(gd8`gdX h^hgd*9 DDD D)D*D+D8DyDzDDDDDDDDʸzm_Q_C5C_h['hSOJQJ]^Jh['hROJQJ]^Jh['hveOJQJ]^Jh['hrVOJQJ]^Jh['huA(OJQJ^Jh['hrVOJQJ^Jh['hrV5OJQJ^J h['huA(CJOJQJ^JaJ#h['hSc5CJOJQJ^JaJ#h['htv5CJOJQJ^JaJ#h['hX 5CJOJQJ^JaJ)h['hB* CJOJQJ^JaJphh['hHOJQJ^JaJDDD E+E,E-E.EEEHEaEbEfEEEEETFUFŴn\K=0h['h2OJQJ^Jh['h25OJQJ^J h['hrVCJOJQJ^JaJ#h['hSc5CJOJQJ^JaJ#h['htv5CJOJQJ^JaJ#h['hX 5CJOJQJ^JaJ h['hCJOJQJ^JaJ h['hjxCJOJQJ^JaJ h['hScCJOJQJ^JaJh['huA(5OJQJ^Jh['h6+nOJQJ^Jh['hmHOJQJ]^Jhh['hveOJQJ]^Jh.E/E`EbEEETFUFF2GqGG>H?HHHIaIII`J & F $Ifgd:Hk & F $Ifgdw7 $Ifgdi. h$If^hgdw7 & F $Ifgdw7 $IfgdrVgd8`gdX UFFFFFFFGG1G2G;GpGqGGGGGG;H=H̿󱣱|oaSaSaE7h['h!cOJQJ]^Jh['hyOJQJ]^Jh['h`c OJQJ]^Jh['h(OJQJ]^Jh['hk:OJQJ^Jh['hjDwOJQJ^Jh['h`c OJQJ^Jh['hFUOJQJ^Jh['hOJQJ]^Jh['hFUOJQJ]^Jh['h(OJQJ^Jh['h6+nOJQJ^Jh['hyOJQJ^Jh['hX/TOJQJ^Jh['h2OJQJ^J=H>H?HHHHHHHHHIIII IӭiYB-jh['h6+nB*OJQJU]^Jphh['hJ0JOJQJ]^J3jh['hxB*OJQJU]^Jph$h['hW B*OJQJ]^Jph-jh['hW B*OJQJU]^Jph$h['hi.B*OJQJ]^Jph$h['hyB*OJQJ]^Jph$h['h6+nB*OJQJ]^Jphh['h(OJQJ^Jh['h\eOJQJ^J I!I"I.I/I0I`IaIbIIIIIIIIIξΫ΅kξ΅TA$h['h2<:B*OJQJ]^Jph-jh['h2<:B*OJQJU]^Jph3jh['hxB*OJQJU]^Jph$h['h6+nB*OJQJ]^Jph$h['hIHYB*OJQJ]^Jph$h['h8|5B*OJQJ]^Jphh['h6+n0JOJQJ]^J-jh['h6+nB*OJQJU]^Jph3jzh['hxB*OJQJU]^JphIIIIIII J J J+J,J.J^J_JξΫgWD4Dh:HkB*OJQJ]^Jph$h['h8|5B*OJQJ]^Jphh['h6+n0JOJQJ]^J3jh['hxB*OJQJU]^Jph$h['h6+nB*OJQJ]^Jph-jh['h6+nB*OJQJU]^Jph$h['heB*OJQJ]^Jphh['he0JOJQJ]^J-jh['h2<:B*OJQJU]^Jph3jh['h2<:B*OJQJU]^Jph_J`JaJbJJJJJJJJKKK%K&K:KʺxbQ?+&h['hpY6>*CJOJQJ^JaJ#h['hpY6CJOJQJ^JaJ h['hpYCJOJQJ^JaJ+h['hB*CJOJQJ\]^Jph"h['hCJOJQJ\]^Jh['hW CJOJQJ\^Jh['hy0xCJOJQJ\^Jh['hS)uCJOJQJ\^Jh['hk:CJOJQJ\^J h['hjCJOJQJ^JaJ#h['h25CJOJQJ^JaJ$h['hi.B*OJQJ]^Jph`JaJbJEKGKCMDMMNSOTOPQ~yyyyytttyojgd9>gd#Kgd:Hkgdk:kdn$$Ifl      `'`'  t 0      644 l` alp yt :K;KLLLMLNL̼̝̝̍}k}[K;[h['hjCJOJQJ\^Jh['h!j CJOJQJ\^Jh['h]f>CJOJQJ\^J"h['he>*CJOJQJ\^Jh['heCJOJQJ\^Jh['hSCJOJQJ\^Jh['hSDCJOJQJ\^Jh['hk:CJOJQJ^Jh['hk:5CJOJQJ^Jh['hk:CJOJQJ\^J h['hpYCJOJQJ^JaJ#h['hpY6CJOJQJ^JaJNLRL[LbLcLnLLLLLLLLLL(M.MBMCMDMMzj]M6,h+h:Hk56>*CJOJQJ\^JaJh['h:HkCJOJQJ\^Jh+ECJOJQJ\^Jh['h!j CJOJQJ\^Jh['hCJOJQJ\^Jh['hjCJOJQJ\^Jh['hCJOJQJ\^JhhCJOJQJ\^JhhjCJOJQJ\^J"h['h`c >*CJOJQJ\^J"h['h]f>>*CJOJQJ\^J"h['hj>*CJOJQJ\^JMMNNNNNNNNNNNNN"OPOROSOTOXOνrbK,h+h#K56>*CJOJQJ\^JaJh['hsUCJOJQJ\^J&h^h:Hk>*CJOJQJ\^JaJhh:HkCJOJQJ\^J'hh:Hk>*CJOJPJQJ^JaJ$hh:HkCJOJPJQJ^JaJ!h:Hk>*CJOJPJQJ^JaJ'hjRh:Hk>*CJOJPJQJ^JaJh:HkCJOJPJQJ^JaJh:HkCJOJQJ\^JXOYOOOO P PPPPPPPQQͯ䘁jUjA.%h['h#K5>*CJOJQJ\^J&huxh9>6>*CJOJQJ^JaJ)hh#K56CJOJQJ\^JaJ,h+h#K56>*CJOJQJ\^JaJ-h+hK0J56CJOJQJ\^JaJ-h+h#K0J56CJOJQJ\^JaJ;jh+h i56>*CJOJQJU\^JaJ,h+h i56>*CJOJQJ\^JaJ5jh+h i56>*CJOJQJU\^JaJQQRRRR*SS]TLUVVWOWtW & F $Ifgd2<: & F $Ifgdw7 $Ifgd K h$If^hgd & F $Ifgde & F $Ifgdw7 & F !$Ifgdw7  !$Ifgdw7gd8`gdX gd-gd#KQQRRRRRRRRRRtSSSSSSSSʶ|bJbJ2J2J2J2/h['hOJQJ]^JaJmH nH sH tH /h['h KOJQJ]^JaJmH nH sH tH 2h['h K5OJQJ]^JaJmH nH sH tH #h['h KCJOJQJ\^JaJ&h['hSc5CJOJQJ\^JaJ&h['h45CJOJQJ\^JaJ&h['hX 5CJOJQJ\^JaJ h['hScCJOJQJ^JaJ&h['h-6CJOJQJ]^JaJ h['h-CJOJQJ^JaJSTT7TJTRTXTYT]TqTTTTTTTTU0UKUUU VBV穛qcUJUhOJQJ]^Jh['hBSOJQJ]^Jh['hOJQJ]^Jh['hSOJQJ]^Jh['h)JOJQJ]^Jh['heOJQJ]^Jh['h KOJQJ]^Jh['h'OJQJ]^J/h['hSOJQJ]^JaJmH nH sH tH /h['hOJQJ]^JaJmH nH sH tH /h['h KOJQJ]^JaJmH nH sH tH BVHVVVVVVWWWW'W(W)W4WǴjW=j-h['h0JOJQJ\^J3jh['hF(B*OJQJU\^Jph$h['hB*OJQJ\^Jph-jh['hB*OJQJU\^Jphh['h K5OJQJ\^Jh['h15OJQJ\^J$h['hTB*OJQJ]^Jph$h['h1B*OJQJ]^Jphh['h'OJQJ]^Jh['heOJQJ]^Jh['hBSOJQJ]^Jh['h ^OJQJ]^J4WLWMWNWOWPWiWjWkWrWsWtWuWvWWŲn^N=, h['hvtCJOJQJ^JaJ h['h/CJOJQJ^JaJh['h K5OJQJ\^Jh['hT5OJQJ\^J3jOh['h\B*OJQJU\^Jph$h['h'B*OJQJ\^Jph-jh['h'B*OJQJU\^Jph$h['h1B*OJQJ\^Jph$h['hZB*OJQJ\^Jph-jh['hB*OJQJU\^Jphh['h10JOJQJ\^JtWuWvWWWW#Z$Z![j\k\\^~yyymhhmmmmmgde  !7$8$gdegd1kd$$Ifl      `'`'  t 0      644 l` alp yt WWWWWWWWWW0XIXJXfXvXXXY!Y"Y-YGY^YiYYY$Z-ZNZêêÒÁssssssssZ1hh&q56>*CJOJQJ^JaJmH sH h`CJOJQJ^JaJ h['heCJOJQJ^JaJ.hhe56CJOJQJ^JaJmH sH 1hh56>*CJOJQJ^JaJmH sH 1hhe56>*CJOJQJ^JaJmH sH  h['hvtCJOJQJ^JaJ#h['hvt>*CJOJQJ^JaJNZPZQZZZZ[[[ [![u[[ȯt\C0 h`CJOJQJ^JmH sH $h['heCJOJQJ^JmH sH 1hhe56>*CJOJQJ^JaJmH sH .hhe56CJOJQJ^JaJmH sH 2hhBS0J56CJOJQJ^JaJmH sH @jkhh i56>*CJOJQJU^JaJmH sH 1hh i56>*CJOJQJ^JaJmH sH :jhh i56>*CJOJQJU^JaJmH sH 1hhBS56>*CJOJQJ^JaJmH sH  [i\j\k\\\\\\]+].]]]]]^ ^^G^ȯ~mYE&h['h45CJOJQJ\^JaJ&h['hSc5CJOJQJ\^JaJ h['heCJOJQJ^JaJ.hhe56CJOJQJ^JaJmH sH 1hh`56>*CJOJQJ^JaJmH sH 1hhe56>*CJOJQJ^JaJmH sH *h['he5>*CJOJQJ^JmH sH h['heCJOJQJ^J$h['heCJOJQJ^JmH sH ^ ^Q^^^_^7_8_%a&aQ|kd($$Ifl p''  t 0 644 lalp ytF $IfgdgOh^hgd6u -DM gd6u`gd8gd gd1G^W^]^^^_^7_8_c___U`V``````ij{kZM*OJQJ\^J#h['h6uCJOJQJ\^JaJ)h['h6uB*CJOJQJ^JaJph"""!h['h6uB* OJQJ^Jph&h['hSc5CJOJQJ\^JaJ&h['h45CJOJQJ\^JaJ&h['h 5CJOJQJ\^JaJ`$a%a&a6d7dadbdndodqdrdsdddd͸vbN:(#h['h'CJOJQJ\^JaJ&h['hSc5CJOJQJ\^JaJ&h['h45CJOJQJ\^JaJ&h['hj5CJOJQJ\^JaJ h['h6uCJOJQJ^JaJ-h['h6u0JB*CJOJQJ^JaJphU2jh['h6uB*CJOJQJU^JaJph""")h['h6uB*CJOJQJ^JaJph"""%h['h6uB*CJOJQJ^Jph$h['h6u6B*OJQJ^Jphh? 5OJQJ\^J&a'aqdrdddeeeLGgdGkd$$Ifl      `'`'  t 0      644 l` alp yt $Ifgd'gd8` & Fgd(.z -DM gd6u -DM gd:Hkddddeeee>eDeIeRe_eeeeeeeeƶooXA,h['h B*CJOJQJ\^JaJph,h['hScB*CJOJQJ\^JaJph#h['hJQCJOJQJ\^JaJ#h['h~CCJOJQJ\^JaJ#h['hScCJOJQJ\^JaJ h['hScCJOJQJ^JaJh['h'5OJQJ\^Jh['h'OJQJ\^Jh['h[)OJQJ\^Jh['h<OJQJ\^Jh['h<5OJQJ\^JeeeeeeeeeeeeefQfRf|f촤o\oI9hgOhSMCJOJQJ\^J%hgOhP5CJOJQJ\]^J%hgOhj5CJOJQJ\]^J%hgOhSM5CJOJQJ\]^J#h['hSMCJOJQJ\^JaJh['h'OJQJ\]^Jh['h(.zOJQJ\]^J!h['hSc6OJQJ\]^J#h['hScCJOJQJ\^JaJ)h['hSc>*䴳ϴ]^&󳧳䴳ϴ]^eehh< & FgdW<kdu$$Ifl      `'`'  t 0      644 l` alp yt $If^gdw7gdSMgd' |fffgggghh1h2h=h>ٳ³hb2'05Oϴ'<5OJQJ^JaJh['h45OJQJ^JaJh['h{~~5OJQJ^JaJ'h['hvt0JCJOJQJ\^JaJ,jh['hvtCJOJQJU\^JaJ#h['hvtCJOJQJ\^JaJ#h['hScCJOJQJ\^JaJh['hSM5OJQJ^JhLghSMCJOJQJ^JhhSMCJOJQJ\^J"hhSMCJOJQJ\]^Jhhhhhhhhhi#i)ijikiqi7jGjHjƯrcWJ=/h:Hkh OJQJ]^Jh['h OJQJ^Jh['hkOJQJ^JhCJOJQJ^Jh['hSCJOJQJ^Jh['h%vCJOJQJ^Jh['h<CJOJQJ^Jh['h<CJOJQJ^Jh['h<5CJOJQJ^J-h['h<OJQJ^JaJfHq 0h['hSc5OJQJ^JaJfHq h['h45OJQJ^JaJh['hW<5OJQJ^JaJhhhqiHj-kk#l & F $Ifgd * & F $Ifgdw7  & F $Ifgdw7 $If^gdw7^gd8`Hjj+k,kk"l#l$l%lIlOl]lllll mmmmmmmmm}p}p}p}p}pcYKh`h:Hk>*OJQJ^Jh OJQJ^Jh['hZ OJQJ^Jh['hHOJQJ^Jh['hjOJQJ^Jh['hScOJQJ^Jh['hScOJQJ^JaJh['h<5OJQJ^Jh['h<OJQJ^Jh['h>`OJQJ^Jh['h}OJQJ]^Jh['hkOJQJ^Jh['h OJQJ^Jh:HkOJQJ^J#l$l%lmmwnnn8oooo~xxxoooooxf^gd ^gd:Hk^kd $$Ifl      `'`'  t 0      644 l` alp yt mmmmm0n7nunvnwnxnnnnnn6o7o8o9oooooooooop~jYLh['h OJQJ^J h|.h CJOJQJ^JaJ&h&Oh 56CJOJQJ^JaJ)h|.h]f>56>*CJOJQJ^JaJ)h|.h 56>*CJOJQJ^JaJh['h:HkOJQJ^Jh>*OJQJ^Jh`h:Hk>*OJQJ^Jhh:HkOJQJ^Jh *>*OJQJ^Jh&h:Hk>*OJQJ^Jh:Hk>*OJQJ^Jp%p7ppppppqqq\qeqnqoqַ{gVEV4 h['hn CJOJQJ^JaJ h['hHCJOJQJ^JaJ h['hScCJOJQJ^JaJ&h['hSc5CJOJQJ\^JaJ&h['h/5CJOJQJ\^JaJ&h['h45CJOJQJ\^JaJ&h['hx5CJOJQJ\^JaJ#h['hSc5CJOJQJ^JaJh['hs hOJQJ^Jh['h OJQJ^Jh['hs h6OJQJ^Jh['h 6OJQJ^Joppqqrr'r(r7rrr3sttu `'@$Ifgdw7 `'@$If^gdw7  & F $Ifgd;G `'@$If^gd & F `'@$Ifgd `'@$Ifgd  `'@gd8` `'@^^gd oqpq|q~qqqqqqqqrrr'r(r6r7rlr޼ͼv_OA1h['h >*OJQJ]^Jh['h OJQJ\^Jh['h 5OJQJ]^J,h['hOZB*CJOJQJ]^JaJph#h['hY5CJOJQJ^JaJ#h['h['5CJOJQJ^JaJ h['hYCJOJQJ^JaJ h['hUCJOJQJ^JaJ h['hScCJOJQJ^JaJ h['h)HCJOJQJ^JaJ h['hn CJOJQJ^JaJ h['hTCJOJQJ^JaJlrrr%s1s2s3sssttttttttuнН|fVH8h['htx5OJQJ]^Jh['hbMOJQJ]^Jh['he0JOJQJ]^J*jh['h iOJQJU]^Jh['h iOJQJ]^J$jh['h iOJQJU]^Jh['heOJQJ]^J"hh;G5OJQJ]^JaJ%h['he5>*OJQJ]^JaJ%h['h;G5>*OJQJ]^JaJh['h;GOJQJ]^Jh['h OJQJ]^Juu/u8uVukulumunuwuuuuuuuuuvvv!vDvZvvvw̾saQCh['htrc5OJQJ^Jh['h)H5>*OJQJ^J"h['h)H5OJQJ]^JaJh['h%\5OJQJ^J$h['h)H5B*OJQJ^Jphh['h9a5OJQJ^Jh['h)H5OJQJ^Jh['hsD5OJQJ^Jh['h;G5OJQJ^Jh['h9aOJQJ^JhOOJQJ^Jh['h)HOJQJ^Jh['hbM5OJQJ]^Jumuuvax7y8y9yyd^U $Ifgd{ `'@kdb!$$Ifl      `'`'  t 0      644 l` alp yt  & F $Ifgdw7  & F $Ifgd9aw_x`xaxexx yyy y*y,y6y7y8y9yyyyyǹǬǟǟǒk]PL5,h['hOB*CJOJQJ]^JaJphhOh *hOOJQJ^Jh *hO5OJQJ^J&hbMB*CJOJQJ]^JaJph$h['h<B*OJQJ]^Jphh['h6OJQJ^Jh['h]OJQJ^Jh['h"OJQJ^Jh['htx>*OJQJ^Jh['htxOJQJ^Jh['h)H5OJQJ^Jhh)H5OJQJ^Jh['h)H5>*OJQJ^Jyyyzz_zyzzzz{3{{ulugb```[gdgdegd[' `'@gdO `'@kd "$$Ifl      'F'      t 0      644 lB` alp yt{ yyzzzAzDz^z_zzzzzzzzzǰ|kZZEZ4 h['h*NCJOJQJ^JaJ)h['hScB*CJOJQJ^JaJph3f h['hScCJOJQJ^JaJ h['heCJOJQJ^JaJ)h['h['B*CJOJQJ^JaJph3fhOCJOJQJ^JaJ h['hOCJOJQJ^JaJ,h['hOB*CJOJQJ]^JaJph/hfHhO6B*CJOJQJ]^JaJph#hfHhOCJOJQJ\^JaJhfHhOCJOJQJ^Jzz{{3{{{{{{{{8|:|ɴzgTg=%/h *hO6B*CJOJQJ]^JaJph,h *hOB*CJOJQJ\^JaJph%hOhOB*CJOJQJ^Jph%h *hOB*CJOJQJ^JphhScCJOJQJ^JaJ huT^hOCJOJQJ^JaJh *hOOJQJ^Jh *hO5OJQJ^J)h['hScB*CJOJQJ^JaJph)h['hScB* CJOJQJ^JaJph h['hScCJOJQJ^JaJ h['h['CJOJQJ^JaJ 3{{{{:|;|{||||}rpgpbbp]Xgdegd['gdO `'@gdOkd"$$Ifl      'F'      t 0      644 lB` alp yt{ $Ifgd{ :|||||}}1}4}\}}}}}}}}}}ՖlWB0B#h:B*CJOJQJ^JaJph)hgOh0&B*CJOJQJ^JaJph)hOh0&B*CJOJQJ^JaJph(hgOhOB*OJQJ\^JaJph(hgOh['B*OJQJ\^JaJph(hgOh0&B*OJQJ\^JaJph)hgOheB*CJOJQJ^JaJph(hgOheB*OJQJ\^JaJph)hgOh['B*CJOJQJ^JaJph)hgOhOB*CJOJQJ^JaJph}}\}}}}}}~ $Ifgd{ V PgdgOgd0&gd0&gd['gd}}?~~~~~~~),Thnrst˶zePe;.h['h*NOJQJ^J(hgOhB*OJQJ\^JaJph(hgOh['B*OJQJ\^JaJph(hgOh0&B*OJQJ\^JaJph(hgOheB*OJQJ\^JaJph#hOB*CJOJQJ^JaJph)hgOh['B*CJOJQJ^JaJph)h['hOB*CJOJQJ^JaJphhOh *hOOJQJ^Jh *hO5OJQJ^J)h['h0&B*CJOJQJ^JaJph~~~~Tst6{vqlgqb]P $If^gdgOgd*Ngdgdegdegd['gd0&kd#$$Ifl      'F'      t 0      644 lB` alp yt{ t678ӀMNсԿ~i\J5~)ha;hOB*CJOJQJ^JaJph#h:B*CJOJQJ^JaJphh['hOOJQJ^J)h *hOB*CJOJQJ^JaJph)h#hOB*CJOJQJ^JaJph)hhOB*CJOJQJ^JaJph,ha;hO>*B*CJOJQJ^JaJph)h%hOB*CJOJQJ^JaJphh9aOJQJ^JhOh:5CJOJQJ^JhgOhO5CJOJQJ^J678с-ab~upuppppkpb !gdOgdOgdO^gd9akdJ$$$Ifl      `'`'      t 0      644 l` alp ytO -J_abe˂oZH6HZ#h:B*CJOJQJ^JaJph#hOB*CJOJQJ^JaJph)h#hOB*CJOJQJ^JaJph)ha;hOB*CJOJQJ^JaJph)h%hOB*CJOJQJ^JaJph"hOB*OJQJ\^JaJph(h *hOB*OJQJ\^JaJph)hChOB*CJOJQJ^JaJph)hwhOB*CJOJQJ^JaJph)h yhOB*CJOJQJ^JaJph)TVfz| 0ԾԗkYkYkD/)hgOh['B*CJOJQJ^JaJph)hgOh*NB*CJOJQJ^JaJph#hKnB*CJOJQJ^JaJph)h['h*NB*CJOJQJ^JaJph,hgOh*N5B*CJOJQJ^JaJph#h['h9aCJOJQJ\^JaJ)h *hOB*CJOJQJ^JaJph+h#hO6B*OJQJ\^JaJph(h *hOB*OJQJ\^JaJph+h%hO6B*OJQJ\^JaJph)TUVfg [ڄۄ$If $$Ifa$gdgd $ a$gd*N  P!gdgO V^gdgOgd*N$gd*Ngd9agdOgdO03DJnowڄۄծp\Lz{23lvҽҨҖo^K8K$h['hp5B*OJQJ^Jph$h['hOZ5B*OJQJ^Jph h['hLeCJOJQJ^JaJ)h['h;G6CJH*OJQJ\^JaJ#h['h;G5CJOJQJ^JaJ#h['heCJOJQJ\^JaJ)h['h+B*CJOJQJ^JaJph)h['h6qB*CJOJQJ^JaJph)h['heB*CJOJQJ^JaJph/h['he5B*CJOJQJ\^JaJph7_z{|}~ $IfgdF$ & F 885$7$8$9DH$^8a$gde MDD8 $$Ifa$gdF $IfgdFkd%$$If4FqH&qN  t06    44 apytFG> $IfgdFkd{&$$If4FqH&qN  t06    44 apytF|| $IfgdFzkdx'$$IfH&H&  t 0644 ap ytF $IfgdFqkd%($$Ifqq t06 44 ap ytF1z $IfgdF|kd($$Ifqq  t 06 44 ap ytF123+`az{xvvvvqqqqqgdz:i$a$gd['gdOZzkdq)$$Ifqq  t 06 44 ap ytF ˉ҉*+N_`ayڴڡǔ|d|P;)h['h5>*䴳ϴ^&'5Cϴ^/'W5B*䴳$ϴ^$/'*5B*䴳$ϴ^$'󰿴ϴ$'!ܰ5B*ϴ$'p5B*ϴ$'w5B*ϴ$'󰿴5B*ϴ$'Y5B*ϴcճ6&',5>*ϴ':5>*ϴ'f5>*ϴ':ϴ':5Oϴ&':6Cϴ^&'6Cϴ^&';,6Cϴ^&'6Cϴ^&'}6Cϴ^)'5>*䴳ϴ^)':5>*䴳ϴ^Սߍ#ʎώԸԫ~~մʱմʜ~N~'P/䴳ϴ'a䴳ϴ"'a6>*䴳ϴ'?䴳ϴ''䴳ϴ':䴳ϴ'8ϴ'᳧6Oϴ'l6Oϴ':6Oϴ':5Oϴ':5>*ϴ؎ݏޏ;<^ϐ91 & F !7$8$gdT  !7$8$gd$Q 5$7$8$9DH$gd\  !7$8$gdL$ !7$8$a$gdflgdz:i  !7$8$gda & F !7$8$^gd.B֎׎؎܎xñobM< h['hB=CJOJQJ^JaJ)jh['hB=CJOJQJU^JaJh['hz:iOJQJ^J"h['h6>*ϴ'l6Oϴ'6Oϴ'a6Oϴ"'a56Oϴ'a6Cϴ'?䴳ϴ':䴳ϴ'l䴳ϴÏۏ܏ݏޏ9:<]^ҿҮvfVfHf:h['hT5OJQJ^Jhh\ 5OJQJ^Jh['hl5>*OJQJ^Jh['h\ 5>*OJQJ^Jh['h}C5>*OJQJ^Jh['h\ OJQJ^Jh['h\ 5OJQJ^Jh['hLOJQJ^J h['hLCJOJQJ^JaJ$h['hfl0JCJOJQJ^JaJ)jh['hB=CJOJQJU^JaJ/j*h['h:CJOJQJU^JaJ^dewyz"&'./7m.beԒՒ֒ڒǹǝǝǹtgZh['hz,OJQJ^Jh['h#tOJQJ^Jh['h5;~OJQJ^Jh['h6OJQJ^Jh['h36OJQJ^Jh['hz,6OJQJ^Jh['h$Q6OJQJ^Jh['hT6OJQJ^Jh['h#t6OJQJ^Jh['h56OJQJ^Jh['h5;~5OJQJ^Jh['h$Q5OJQJ^J1ԒՒG“-._aqrݔޔIJ & F !7$8$^gd.Bh^hgdhgdL 5$7$8$9DH$gdO*$ !7$8$a$gdz,  !7$8$gd#t  !7$8$gdL & F !7$8$gdTڒߒ FTVWzǓΓݓ,-./DEF^_`ԸmZKh['hz,0JOJQJ^J$h['hz,0JCJOJQJ^JaJ/j*h['hCJOJQJU^JaJ h['h`}CJOJQJ^JaJ)jh['h`}CJOJQJU^JaJh['hz,OJQJ^Jh['h\ 6OJQJ^Jh['h#t6OJQJ^Jh['h$Q6OJQJ^Jh['hz,6OJQJ^Jh['h$Q56OJQJ^J`ar̔Քݔޔ 㥕vgvXvgvE%h['hL6>*CJOJQJ]^Jh['hCJOJQJ^Jh['hP/CJOJQJ^Jh['hLCJOJQJ^Jh['h J 5OJQJ\^Jh['h5OJQJ\^Jh['hL5OJQJ\^Jh['hO*5OJQJ^Jh['h3l5>*OJQJ^Jh['hL5>*OJQJ^Jh['hL5OJQJ^Jh['hz,5OJQJ^J9BIJPjܸ|hWH5H%h['hz 76>*CJOJQJ]^Jh['hz 7CJOJQJ^J h['hLCJOJQJ^JaJ&h['hL5CJOJQJ\^JaJh['hP/CJOJQJ^Jh['hCJOJQJ^Jh['hA9CJOJQJ^Jh['hLCJOJQJ^J"h['h^6CJOJQJ]^J"h['h6CJOJQJ]^J"h['hA96CJOJQJ]^J"h['hL6CJOJQJ]^JJOPOP !7$8$^gdz 7 $h^ha$gdz 7 !7$8$^gdz 7h^hgdLh^hgdh $h^ha$gdfl !7$8$^gdfb & F !7$8$^gd.B $h^ha$gdLіҖӖAƱubQA1h['hL6OJQJ]^Jh['hL5OJQJ\^J h['h;:CJOJQJ^JaJ$h['hL0JCJOJQJ^JaJ$h['hfl0JCJOJQJ^JaJ/j*h['hF(CJOJQJU^JaJ h['h=TzCJOJQJ^JaJ)jh['h=TzCJOJQJU^JaJh['hA9OJQJ^Jh['hfbCJOJQJ^Jh['hw.CJOJQJ^Jh['hCJOJQJ^JARz ۘ͘ 2<>NOPQkreP? h['h=TzCJOJQJ^JaJ)jh['h=TzCJOJQJU^JaJh['hz 7OJQJ^J"h['hL6CJOJQJ]^Jh['hP/CJOJQJ^Jh['h/qCJOJQJ^Jh['h5pCJOJQJ^Jh['hLCJOJQJ^Jh['hA-6OJQJ]^Jh['h/q6OJQJ]^Jh['hL6OJQJ]^Jh['h5p6OJQJ]^JklmÙę˙̙ߙҿҲtaO<'(h['hL6>*CJOJQJ\]^J%h['hL6CJOJQJ\]^J"hhZ6CJOJQJ\^J%h['h5p6>*CJOJQJ\^Jh['hZCJOJQJ\^Jh['hLCJOJQJ\^Jh['h J OJQJ^J h['hLCJOJQJ^JaJh['hz 7OJQJ^J$h['hz 70JCJOJQJ^JaJ)jh['h=TzCJOJQJU^JaJ/jg+h['hF(CJOJQJU^JaJIJ+,$a$gdB= & FgdF^h^gd)+ & Fgd)+h^hgd h`hgd $h^ha$gd $h^ha$gdflh^hgdLgd & F !7$8$^gd.Bgd J h^hgdhߙEFGHIJOuɴɴs`S@0h['hL6OJQJ]^J$h['hL56OJQJ\]^Jh['hOJQJ^J%hh6CJOJQJ\]^J-hh6CJOJQJ\]^JmH sH (h['h5p6>*CJOJQJ\]^J(h['h/q6>*CJOJQJ\]^J(h['hL6>*CJOJQJ\]^J%h['hL6CJOJQJ\]^Jh['hLCJOJQJ\^J%hhL6CJOJQJ\]^Ju~̛͛Λ*3໪l[J:h['h)+6OJQJ]^J h['hLCJOJQJ^JaJ h['hVp|CJOJQJ^JaJ$h['hL0JCJOJQJ^JaJ$h['hfl0JCJOJQJ^JaJ/j+h['hF(CJOJQJU^JaJ h['h=TzCJOJQJ^JaJ)jh['h=TzCJOJQJU^JaJh['h5p6OJQJ]^Jh['hL6OJQJ]^Jh['h/q6OJQJ]^J3BȜMQnвp^J^6&h['hF^h>*CJOJQJ]^JaJ&h['h)+>*CJOJQJ]^JaJ#h['h)+CJOJQJ]^JaJ h['hLCJOJQJ^JaJ h['hF^hCJOJQJ^JaJh['hy5OJQJ]^Jh['h)+5OJQJ]^Jh['hyOJQJ]^Jh['h36OJQJ]^Jh['hDV6OJQJ]^Jh['hL6OJQJ]^Jh['hy6OJQJ]^J'*+,x{ȻrbM< h['h=TzCJOJQJ^JaJ)jh['h=TzCJOJQJU^JaJh['hL6OJQJ]^J&h['hw>*CJOJQJ]^JaJ#h['hwCJOJQJ]^JaJ#h['hF^h>*CJOJQJ^JaJ h['hF^hCJOJQJ^JaJh['h)+OJQJ^J h['h)+CJOJQJ^JaJ&h['hF^h>*CJOJQJ]^JaJ#h['hF^hCJOJQJ]^JaJ !'\+,^_ҿҮ~pW*CJOJQJ^JaJfHq 5h['hp0J'CJOJQJ^JaJfHq 1h['hpCJOJQJ^JaJfHq h['hpOJQJ\^Jh['hp6OJQJ]^Jh['hJ5OJQJ\^Jh['ht*OJQJ^Jh['hOJQJ^J h['hpCJOJQJ^JaJ1h%hpCJOJQJ^JaJfHq 4h['hp>*CJOJQJ^JaJfHq :h['hp6>*CJOJQJ]^JaJfHq >h['hp0J'6>*CJOJQJ]^JaJfHq eͤΤϤǹudLu9u+h['h*I 5OJQJ^J$h['hw0JCJOJQJ^JaJ/j3-h['hwCJOJQJU^JaJ h['hwCJOJQJ^JaJ)jh['hwCJOJQJU^JaJh['hwCJOJQJ^J#h['hw5CJOJQJ^JaJh['hw5OJQJ^Jh['h >*OJQJ^J h['hCJOJQJ^JaJ)jh['hCJOJQJU^JaJ$h['h0JCJOJQJ^JaJߥmo+ʼ}jVCj0$hPvhCJOJQJ^JmH sH $hChCJOJQJ^JmH sH 'hxh>*CJOJQJ^JmH sH $h/mhCJOJQJ^JmH sH h/mh5OJQJ]^Jh5OJQJ]^J#h['hM5CJOJQJ^JaJh['hBH&6OJQJ\^Jh['h36OJQJ^Jhxh6OJQJ^Jh5OJQJ^Jh['h*I 5OJQJ^Jh['h.5OJQJ^JߥnoUV[\ jkªh^hgdZ $h^ha$gd & F !7$8$^gdgdh^hgdgdMX^XgdY h^hgd++07TUV\atĵ}iY}J:,hMCJOJQJ^JaJh/mh5OJQJ]^Jh/mhCJOJQJ^JhCJOJQJ^JmH sH 'hxh>*CJOJQJ^JmH sH $h/mhCJOJQJ^JmH sH  h/mhCJOJQJ^JaJ&h/mh5CJOJQJ\^JaJhchCJOJQJ^J$hPvhCJOJQJ^JmH sH 'hZ h>*CJOJQJ^JmH sH 'hZ h)>*CJOJQJ^JmH sH   jéĩ789:˪ʹ~jVF6h['hM6>*OJQJ^Jh['hM6OJQJ\^J&h['hM5CJOJQJ\^JaJ&h%hM5CJOJQJ\^JaJ)h['hM6>*CJOJQJ\^JaJ&h%hM6CJOJQJ\^JaJ#h['hMCJOJQJ\^JaJ!h['hM56>*OJQJ^Jh['hM5OJQJ^JhCJOJQJ^JaJh['h6OJQJ^Jh6OJQJ^J˪̪ت٪ޫ_`QRͼkTCͼ5hZ 56>*OJQJ^J!h['hM56>*OJQJ^J,h['hMCJOJQJ^JmH nH sH tH (h['hMOJQJ^JmH nH sH tH +h['hM>*OJQJ^JmH nH sH tH .h['hM6>*OJQJ^JmH nH sH tH h['hM5OJQJ^J h['hMCJOJQJ^JaJ#h['hMCJOJQJ\^JaJ&h['hM>*CJOJQJ\^JaJh['hMOJQJ^Jªޫ߫_`QRBCdelm&'  !7$8$gdZ gdZ 7$8$gdM$a$gdMgdMƭǭ?ABdѾѾtcM<!h['hM56>*OJQJ^J+h`hZ 6B*CJOJQJ]^Jph!hZ CJOJQJ]^JmH sH *h%hZ 6CJOJQJ]^JmH sH "h`hZ 6CJOJQJ]^J"h%hZ 6CJOJQJ]^Jh`hZ >*CJOJQJ^J%h`hZ 6>*CJOJQJ]^Jh`hZ CJOJQJ^JhZ CJOJQJ^JaJ!h`hZ 56>*OJQJ^Jdel}%&~fròIJѳᣒq]q]qMh['hM6OJQJ\^J&h['hM>*CJOJQJ\^JaJ h['hMCJOJQJ^JaJh%hM56OJQJ^J!h['hM56>*ϴ'M56Oϴ%M䴳ϴ'2<:CJOJQJ^Jh['hM>*CJOJQJ^Jh['hMCJOJQJ^Jh['hM5>*OJQJ^J)*tuòIJŲAxy- & F !7$8$^gd.Bh`hgd_5gdGgdIr$a$gdnl^gd*I X^XgdY -D5$7$8$9DH$M `gdM-D5$7$8$9DH$M gdMIJŲƲ!7>Ay͵ޢ|l\l|L?. h['h_5CJOJQJ^JaJh['hOJQJ^Jh['hG6OJQJ]^Jh['h3l5>*OJQJ^Jh['hG5>*OJQJ^Jh['hG5OJQJ^J/jh['hnl5CJOJQJU\^JaJ$h['hnl0JCJOJQJ^JaJ/j-h['hnlCJOJQJU^JaJ h['hnlCJOJQJ^JaJ)jh['hnlCJOJQJU^JaJh['hBOJQJ^JƳ-.yz{˵ĵeQA1h['hG5OJQJ\^Jh['h5OJQJ\^J'h['h0JCJOJQJ\^JaJ2j.h['hCJOJQJU\^JaJ#h['hCJOJQJ\^JaJ,jh['hCJOJQJU\^JaJh['hXOJQJ^Jh['hXCJOJQJ^Jh['hX6OJQJ]^Jh['hOJQJ^Jh['h>*CJOJQJ^Jh['hCJOJQJ^J-.yzkh^hgdG $h^ha$gdB=gdG & F !7$8$^gd.Bh`hgdgdV $h^ha$gd & F 7$^gdXh^hgdXh`hgdXgd˵$-tuRX·޷ôxkZkFZ2'h['hB=0JCJOJQJ\^JaJ'j.h['hB=OJQJU^J!jh['hB=OJQJU^Jh['hB=OJQJ^Jh['hfqsCJOJQJ^Jh['h*CJOJQJ^Jh['h:NaCJOJQJ^Jh['hGCJOJQJ^Jh['hL:CJOJQJ^Jh['hGOJQJ^Jh['hVp|5OJQJ\^Jh['hG5OJQJ\^Jh['hfqs5OJQJ\^J޷߷jk̹GZպֺweUA'hohF>*CJOJQJ^JmH sH h['h4G>*CJOJQJ^J"h['h4G6>*CJOJQJ^Jh['h4GOJQJ^Jh['h4GCJOJQJ^Jh['h:NaCJOJQJ^Jh['hJQCJOJQJ^Jh['hCJOJQJ^Jh['hG5OJQJ^Jh['h5OJQJ^J#h['hhCJOJQJ\^JaJ!jh['hB=OJQJU^Jغٺtuvy !7$8$^gd( & F !7$8$^gd.Bh`hgd gdhgd gdhl gd l  $h^ha$gd{Ngd( !7$8$^gd4G !7$8$^gd4G ֺ׺غٺں 5ZöÎ|oaSC3h['h3l5>*OJQJ^Jh['hh5>*OJQJ^Jh['hhOJQJ]^Jh['hh5OJQJ^Jh['h :OJQJ^J#h['h{NCJOJQJ\^JaJ'h['h{N0JCJOJQJ\^JaJ'j.h['h{NOJQJU^Jh['h{NOJQJ^J!jh['h{NOJQJU^Jh['h(OJQJ^Jh['h>*CJOJQJ^Jhoh4GCJOJQJ^JZckrstuvǻ̻ѻ޻7FHдwhYhJ;h;Yh;h['hBCJOJQJ^Jh['hhCJOJQJ^Jh['h:NaCJOJQJ^Jh['h)PeCJOJQJ^Jh['h25OJQJ\^Jh['h5OJQJ\^Jh['hB5OJQJ\^Jh['hhOJQJ^Jh['hh5OJQJ^Jh%hh5OJQJ^Jh['hh5>*OJQJ^Jh['h3l5>*OJQJ^Jh['h:Na5>*OJQJ^J¼Ҽݼ޼qaQAQ1h['h6+n5>*OJQJ^Jh['hG5OJQJ\^Jh['h6+n5OJQJ\^Jh['hXH5OJQJ\^J$h['hh0JCJOJQJ^JaJ$h['hB=0JCJOJQJ^JaJ/jT/h['h14.CJOJQJU^JaJ h['h14.CJOJQJ^JaJ)jh['h14.CJOJQJU^JaJh['h(OJQJ^Jh['hhCJOJQJ^Jh['h)PeCJOJQJ^J߼*+SZ}~ !7$8$^gd< & F !7$8$^gd.Bh`hgd gd  !7$8$gdFo$a$gd< & F !7$8$^gd 1h`hgd(gd6+ngd6+ngdG$a$gdB= '*+Sagsz{$ҽpaOa?h['hJ>*CJOJQJ^J"h['hJ6>*CJOJQJ^Jh%hJCJOJQJ^Jh['hZWCJOJQJ^Jh['heCJOJQJ^Jh['hlCJOJQJ^Jh['hJCJOJQJ^J h['hJCJOJQJ^JaJ)h['h6+nB* CJOJQJ^JaJphh['h6+n5OJQJ^Jh['h6+n5>*ϴ'35>*ϴ$'(=վ¾۾ܾھϹᩚx*CJOJQJ^JmH sH "h['h6>*䴳ϴ%6Cϴ'䴳ϴȾ()7ʿξάΌ|>+$'<0JCJOJQJ^JaJ/j20h['hF(CJOJQJU^JaJ h['h<CJOJQJ^JaJ)jh['h<CJOJQJU^JaJh['h<OJQJ\^JaJh['h6+nCJOJQJ\^Jh%h6ZCJOJQJ\^J"h['h6Z>*CJOJQJ\^Jh['hJQCJOJQJ\^Jh['h6ZCJOJQJ\^J h['h6+nCJOJQJ^JaJ h['hJCJOJQJ^JaJݿs d^gdi4 & F-D5$7$8$9DH$M gdi4 $da$gdi4d^`gd6+n adgd !7$8$^gdr & F !7$8$^gd.Bh`hgd  !7$8$^gd< ݿ2;νέΝtcR9cRRc1h['hi4CJOJQJ^JaJfHq !h['hi4B*OJQJ^Jph""" h['hi4CJOJQJ^JaJh['h)OJQJ^Jh['hi45OJQJ^Jh['hrOJQJ\^Jh['h6+nCJOJQJ\^Jh['hlCJOJQJ\^J!h% CJOJQJ\^JmH sH h['h)CJOJQJ\^J h['h6+nCJOJQJ^JaJh['h<OJQJ\^JaJFIe~h`hgd2<:gd2<:$a$gd<^gdN-D5$7$8$9DH$M ^gdi4 & F-D5$7$8$9DH$M gdi4 $da$gdi4-D5$7$8$9DH$M gdi4 & F5$7$8$9DH$gdi4 '()FGIe2˳ܠ܏~n^N^9( h['h2<:CJOJQJ^JaJ)jh['h2<:CJOJQJU^JaJh['h<CJOJQJ\^Jh['h2<:CJOJQJ\^Jh['h2<:6OJQJ^JtH h['h2<:CJOJQJ^JaJ h['h2<:CJOJQJ^JaJ$h['h<0JCJOJQJ^JaJ/j0h['h<CJOJQJU^JaJ h['h<CJOJQJ^JaJ)jh['h<CJOJQJU^JaJh['h<5OJQJ^JeQSTefab |)9Dgduh^hgdu,h`hgdu,h^hgdu,gdu , h^hgdu |)h^hgdu^gdN$a$gd2<:^gd2<:gd2<:h`hgd2<:234QRST:DEҿұveWEW0E)js1hu6B*CJUaJph#jhu6B*CJUaJphhu6B*CJaJph h *hu6B*CJaJphh`hu6OJQJ]^JhqOhu5OJQJ\^Jhu5OJQJ\^Jh['h<5OJQJ^Jh['h2<:5OJQJ^J$h['h2<:0JCJOJQJ^JaJ)jh['h2<:CJOJQJU^JaJ/j1h['h2<:CJOJQJU^JaJby|P[YDFGκά|qdq|qdq|d|d|q|d|d|] hChuh *hu0J)B*phh *huB*ph[\\ h *hu h`huCJOJQJ^JaJhu6OJQJ]^Jhu6OJQJ^Jh *hu6OJQJ^J&h *hu56B*CJ\aJph h *hu6B*CJaJph#jhu6B*CJUaJphhGhu0J6CJaJ!GHwxh^hgd1 & F !7$8$^gd.Bh`hgd h^hgdrgd1 hh^h`gd1$a$gd7Ggdm%J-DM [$\$^gduGHI_`a}~ʰܜ܊xhZJ:JZ*h['hr6OJQJ]^Jh['h3l5>*OJQJ^Jh['h15>*OJQJ^Jh['h15OJQJ^Jh['h15OJQJ\^J#h['h >CJOJQJ\^JaJ#h['hbTCJOJQJ\^JaJ'h['h7G0JCJOJQJ\^JaJ2j2h['h:CJOJQJU\^JaJ#h['h7GCJOJQJ\^JaJ,jh['h7GCJOJQJU\^JaJh['hROJQJ^Jwx123FIXY²vdTE6v6h['hCJOJQJ^Jh%hCJOJQJ^Jh%hyK6CJOJQJ^J"h['hyK6>*CJOJQJ^Jh['hyKCJOJQJ^Jh['hJQCJOJQJ^Jh['h!hCJOJQJ^Jh['h1CJOJQJ^Jh['h15OJQJ\^Jh['h5OJQJ\^Jh['h15OJQJ^Jh['hr6OJQJ]^Jh['h.6OJQJ]^JYZ]abp]F]p7h['hlCJOJQJ^J-h['hA6>*CJOJQJ]^JmH sH %h['h16>*CJOJQJ]^J"h['h16CJOJQJ]^Jh['hACJOJQJ^J$h['hACJOJQJ^JmH sH h['h15OJQJ\^Jh['h1OJQJ^Jh['h1CJOJQJ^Jh['hCJOJQJ^Jh['hyK6CJOJQJ^Jh['h6CJOJQJ^J,-HI & Fgd4Q h^h`gd# & Fgdz>gd4QgdG !7$8$^gd.B$a$gdQ#4 !7$8$^gd/h^hgd  & F !7$8$^gd.Bh`hgd 23@ACj̧̹}fT:f2j2h['hQ#4CJOJQJU\^JaJ#h['hQ#4CJOJQJ\^JaJ,jh['hQ#4CJOJQJU\^JaJh['h/OJQJ^Jh['ht5OJQJ^Jh['hCJOJQJ^J"h['ht6CJOJQJ]^J%h['h16>*CJOJQJ]^J"h['h16CJOJQJ]^J$h['hACJOJQJ^JmH sH h['h1CJOJQJ^J!)-1;@˻wgwYJ;Jh['hkJOJQJ^JaJh['h4QOJQJ^JaJh['h4Q5OJQJ^Jh['h:i5>*OJQJ^Jh['hk5>*OJQJ^Jh['h4Q5>*OJQJ^J&h['h4Q5CJOJQJ\^JaJh['hk5OJQJ\^Jh['h4Q5OJQJ\^Jh['h1CJOJQJ^J!jh['hQ#4OJQJU^J'h['hQ#40JCJOJQJ\^JaJ@LW`eHIZ9:ĵĦĔĆvfUD6h['h4Q5OJQJ^J h['h4QCJOJQJ^JaJ h['hC|yCJOJQJ^JaJh['h_56OJQJ]^Jh['h4Q56OJQJ^Jh['h4Q6OJQJ^J"h['h4Q6OJQJ]^JaJh['h_5OJQJ^JaJh['hOJQJ^JaJh['h4QOJQJ^JaJh['hkJOJQJ^JaJh['h?OJQJ^JaJh['hC|yOJQJ^JaJ9:rtuwxz{}~gd0&h]h &`#$gdgd1h'$a$gdmgd4Q & Fgd.:;<RSTpqrsuvxy{|~ȰِٝseWIsEhAhcNCJOJQJ^JaJhBSCJOJQJ^JaJhv(CJOJQJ^JaJ hmhACJOJQJ^JaJhjhUh['h.BOJQJ^J$h['hC|y0JCJOJQJ^JaJ/j\3h['hF(CJOJQJU^JaJ h['hCJOJQJ^JaJ)jh['hC|yCJOJQJU^JaJ!h['h4QB*OJQJ^Jphظɩyk]OyHDh h0&hAhcNCJOJQJ^JaJheCJOJQJ^JaJhv(CJOJQJ^JaJ hmhACJOJQJ^JaJhcNOJQJ^JaJmH sH hcNhAOJQJ^JaJh['hACJOJQJ^J!hv(0JOJQJ^JmHnHuh['hA0JOJQJ^J%jh['hA0JOJQJU^JhA hA0JjhA0JU$a$gdmgd0&h['h.BOJQJ^JC 0 00&P/R :pBP/ =!8"8#$% J 00P&P/R :pGBP/ =!8"8#$% DpDyK yK 8https://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/hipaa_authorization_form.docyX;H,]ą'c$$If!vh#v8(:V l  t 0      658(` p ytw7$$Ifl!vh#v#v:V l40'6554alf4yt['$$If!vh#v #v#v#v:V  0',5 55544 apytF$$If!vh#v #v#v :V  0',5 55 44 apytF$$If!vh#v #v#v#v:V U 0',5 555/ 44 apytF$$If!vh#v #v#v :V  0',5 55 / 44 apytF$$If!vh#v #vL:V   0',5 5L/ 44 ap ytF{DyK  introduction$$Ifl!vh#v`':V l  t 0      65`'` alp ytDyK yK Jhttps://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/consent_key_information_examples.docxyX;H,]ą'c$$Ifl!vh#v':V l  t 0      65'alp yt{$$Ifl!vh#v':V l t065'alp yt{uDyK  Deception$$Ifl!vh#v`':V l  t 0      65`'alp ytDyK ParticipatinginOtherStudiesDyK ScreeningproceduresDyK interviewquestionnairesDyK  followupwDyK  AudioVideouDyK  futureuse$$Ifl!vh#v`':V l  t 0      65`'alp yt$$Ifl!vh#v`':V l  t 0      65`'alp ytuDyK  interviewoDyK breachDyK breachCertConf$$Ifl!vh#v`':V l  t 0      65`'alp ytsDyK  benefits$$Ifl!vh#v`':V l  t 0      65`'` alp yt$$Ifl!vh#v`':V l  t 0      65`'` alp yt}DyK resereccontidyDyK  datasharingDyK releaseofresearchresultsDyK MandatedReportiDyK COC$$Ifl!vh#v`':V l  t 0      65`'` alp ytDyK yK Dhttps://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/nih_clinical_trial_definition.docxyX;H,]ą'cDyK costsandpaymentqDyK payment$$Ifl!vh#v`':V l  t 0      65`'` alp ytDyK yK Lhttps://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/consent_addendum_employee_payment.docxyX;H,]ą'c$$Ifl!vh#v':V lp  t 0 65'alp ytF$$Ifl!vh#v`':V l  t 0      65`'` alp yt$$Ifl!vh#v`':V l  t 0      65`'` alp yt$$Ifl!vh#v`':V l  t 0      65`'` alp ytDyK yK &https://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/guidelines_lar.docxyX;H,]ą'c$$Ifl!vh#v`':V l  t 0      65`'` alp yt$$Ifl!vh#v':V l  t 0      65'/  B` alp yt{$$Ifl!vh#v':V l  t 0      65'/  B` alp yt{$$Ifl!vh#v':V l  t 0      65'/  B` alp yt{$$Ifl!vh#v`':V l  t 0      65`'/  ` alp ytO$$Ifl!vh#v`':V l t0`'65`'alytT$$If!vh#vq#vN#v :V 4  t06+,5q5N5 4 apytF$$If!vh#vq#vN#v :V 4  t06+,5q5N5 4 apytF$$If!vh#vH&:V   t 06,5H&4 ap ytF$$If!vh#vq:V  t06 ,5q4 ap ytF$$If!vh#vq:V   t 06 ,5q4 ap ytF$$If!vh#vq:V   t 06 ,5q4 ap ytFmDyK INTROiDyK PURsDyK  Section2sDyK  Section2sDyK  Section2sDyK  Section2sDyK  Section2sDyK  Section2sDyK  Section2iDyK RISiDyK RISiDyK RISsDyK  Section5kDyK CONFkDyK CONFkDyK CONFkDyK CONFDyK yK https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.htmlyX;H,]ą'ckDyK CONFmDyK COSTSoDyK Rights^- H02 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH H`H }Normal5$7$8$9DH$_HmH sH tH B@B  Heading 1$$@&a$>*CJ<@<  Heading 2$@&CJ\^@^  Heading 3$$5$9D@&H$a$5>*CJOJQJ\aJZ@Z  Heading 4$5$9D@&H$5B* OJQJ\aJphT@T * Heading 5$5$9D@&H$5CJOJQJ\aJX@X  Heading 6$$5$9D@&H$a$CJ0OJQJ^JaJ0Z@Z  Heading 7$5$9D@&H$>*B* CJOJQJaJphX@X ( Heading 8$h5$9D@&H$^h5OJQJ\aJb @b  Heading 9 $d5$9D@&H$5>*B*OJQJ\aJphDA`D Default Paragraph FontVi@V  Table Normal :V 44 la (k (No List XR@X Body Text Indent 2P^`P5CJH@H  Balloon TextCJOJQJ^JaJV @V &Footer !5$9DH$OJQJaJmHsHtH6U`!6 Hyperlink >*B*phD>@2D Title$5$9DH$a$5OJQJ\2B@B2 Body TextCJHC@RH +Body Text Indent h^hCJ.)@a. Page NumberFP@rF Body Text 25CJW+q\^O^ Blockquote$hhdd5$9DH$]h^h OJQJaJRQ@R Body Text 3 5$9DH$B*OJQJaJphhS@h Body Text Indent 3h5$9DH$^hB*OJQJaJph4@4 Header  !FV`F :FollowedHyperlink >*B*phFF  Footnote Text5$7$8$9DH$PoP HTML Body 7$8$H$OJQJ_HmH sH tH VT@V Block Texth@&]^hB* CJaJphzz / Table Grid7:V 0 5$7$8$9DH$@&`@ Footnote ReferenceH*B'`!B KComment ReferenceCJaJ4@24 K Comment Text#@j@12@ KComment Subject$5\f^@Rf R0 Normal (Web) %dd5$7$8$9DH$[$\$CJOJQJ^JaJ:oa: BH& Footer Char OJQJaJBoqB papple-converted-spaceFoF ;GHeading 8 Char5OJQJ\aJ.X`. M@Emphasis6]JoJ 2<:Heading 5 Char5CJOJQJ\aJFoF :HkBody Text Indent CharCJbob uDefault ,7$8$H$-B*CJOJQJ^J_HaJmH phsH tH PK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] +\E\ (3m7 {OZ1Y 3"j#&(*b,-.B1(45566n89;U=0>>H?@BDDUF=H II_J:KNLMXOQSBV4WWNZ[G^`de|fhHjmpoqlruwyz:|}t0Ny^ڒ`Akߙu3e+˪dIJ˵޷ֺZ$2GY@:nprtuwy|~    "#$&'(*+-n tm0i k#5'*-2,68 :1>@LC.E`JQtW^&aeh#louy3{}~6ۄ11Jª-eoqsvxz{}  !%),6O:Zgx}%%%,,,,-,-.-X-[-w-------.*.75T5o5p55555/6:::@@AA!A.AaAAAAAAA B+BXGGHO(OLOOOjOrOPRRSUXXX6\a\n\`1`=`kll‡ۇ.E_ҎPl͓HdΜŪzޯٲ Zr~(F3QDοH`};SpXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX(/3:<!!T@ @H 0(  0(  B S  ? _Hlt208135193 _Hlt208135194 _Hlt161460353 _Hlt161460354 _Hlt161554067 _Hlt167763176 _Hlt167763177 _Hlt168212365 _Hlt168212366 _Hlt142189238 _Hlt140460932 _Hlt167859407 _Hlt167859408 _Hlt168212498 _Hlt147633660 _Hlt168212545 _Hlt168212602 _Hlt166306959 _Hlt166306960INTROPURSection2 _Hlt161554107 _Hlt166307041 _Hlt161554092 _Hlt335809217 _Hlt166307045 _Hlt166307061 _Hlt166307075 _Hlt162424287 _Hlt161554104 _Hlt166307079 _Hlt161554097 _Hlt161632737 _Hlt161632738 _Hlt166307082 _Hlt381616241 _Hlt166307087 _Hlt381616195 _Hlt381616196 _Hlt162431604 _Hlt162431605 _Hlt161633524 _Hlt166307093 _Hlt335809104 _Hlt167676754 _Hlt167676755 _Hlt335808996RIS _Hlt162172939 _Hlt161554456 _Hlt170894754 _Hlt166307104 _Hlt161554521 _Hlt162172763 _Hlt162172777 _Hlt162172934 _Hlt166307106 _Hlt161554668 _Hlt162172919 _Hlt166307111 _Hlt162172969Section5 _Hlt161557211 _Hlt336592285 _Hlt166307148ALTCONF _Hlt336001512 _Hlt166307155 _Hlt161561857 _Hlt166307158 _Hlt161561904 _Hlt166307161 _Hlt336001681 _Hlt161561941 _Hlt454616777 _Hlt534040693 _Hlt534040694 _Hlt454615569 _Hlt454615558 _Hlt454615534 _Hlt166307164 _Hlt166307201 _Hlt161562057 StateLaws _Hlt470086303 _Hlt470086304 _Hlt471284837 _Hlt471284838COSTS _Hlt166307219 _Hlt161564251 _Hlt161564468 _Hlt161564506 _Hlt161564587Rights _Hlt170634735 _Hlt170634736 _Hlt170634752 _Hlt170634753 _Hlt285702685 _Hlt285702686purpose introduction _Hlt168212597 _Hlt161460368 _Hlt166306963 _Hlt168212482 _Hlt161554070 _Hlt168212532 Deception _Hlt335808804 _Hlt161635016 _Hlt166307013 _Hlt166306976 participationParticipatinginOtherStudies _Hlt166307043 _Hlt161554109 _Hlt161554094 _Hlt163448141 _Hlt163448142Screeningprocedures _Hlt161553211 _Hlt161554102 _Hlt335809227 _Hlt166307059 _Hlt166307072 _Hlt166307077followup _Hlt161554105 _Hlt166307080HIV OLE_LINK1interviewquestionnaire _Hlt161554054 _Hlt166307085 _Hlt161554098 AudioVideo _Hlt162421005 _Hlt162421409 _Hlt381616238 _Hlt381616274 _Hlt166307089 FutureUse OLE_LINK3 _Hlt166307096 _Hlt161633526 _Hlt335809001 _Hlt335809124 _Hlt170894745 _Hlt170894746risks interview _Hlt161554497 _Hlt166307105 _Hlt162172781 _Hlt162172937breachcancer _Hlt166307109 _Hlt161554453 _Hlt162173022 _Hlt162172932breachCertConf _Hlt162172757 _Hlt166307143 _Hlt162172770 _Hlt162172958benefits _Hlt161113529 _Hlt166307151 _Hlt336001501 _Hlt336001502 _Hlt336592297 resereccontid _Hlt161561851 _Hlt166307156 datasharing _Hlt162410438 _Hlt161561903 _Hlt166307160releaseofresearchresults _Hlt454615544 _Hlt166307163 _Hlt454615531 _Hlt454615532 _Hlt161561933 _Hlt336001673MandatedReport _Hlt454615567COC _Hlt161562041 _Hlt166307211 _Hlt161564430costsandpaymentpayment paymentof600 _Hlt166307236 VOLUNTARY _Hlt161566505 _Hlt166307312researcherfinancialdisclosureProductBB^^_____`aaaabbbcck"%,,,-$-%-&-Y-------------".&.&.'.'.'.1_5`5c5g5i5n5n55555558:::<b=@@(A(A,AAAAAAAAABB B"BD H HHHJ>O@O@OCOpOB`MnMnMnMnMnMn{ʇˇˇЇ҇ՇBLSVW_׎ߎP{{~ړ 'rrsuvĪyzǯʯ˯ԯ+055567IIThrs^bqq@@@@@@@@@ @ @ @ @ @@@@@@@@@@@@@@@@ @!@"@#@$@%@&@'@(@)@*@+@,@-@.@/@01@2@3@4@5@6@7@8@9@:@;@<@=@>?#&,,,-%-&-'--------------#.'.'.(.(.(.155555555555558:::*<=@@)A)A-AAAAAAAAABB!B#BD H HHHJ?OAOAODOqO`NnNnNnNnNnNnˇ̇̇чӇև^MTWXnތ؎||ۓ 'sstvwŪȯ˯̯կtRݷ166678IJGist_cqqOOΊъy|ILrtuwxz{}~ xk 2";"1 111FFGUVWV]VtwwQRֆ؆Ç܇:B]eΈֈ8901ӊڊFMNj,F^ތHPNH,xkײSY|޷rtuwxz{}~3333333333333**-.C0D0D0EEM NOOOO0PIPJPfPvPPPPPQ!Q"Q-QGQHQHQ^QiQQQuSSTTjakaggEFGGײײGGqrrtuuwxz{}~**-.C0D0D0EEM NOOOO0PIPJPfPvPPPPPQ!Q"Q-QGQ^QiQQQuSSTTjakaggEFGGײײGGqrrtuuwxz{}~K;d-B&e8aW6d9cO]5ODd7|begq#X2yYv%]Nl}(l%]V.<84`p>+6qXiEf?mO5~9W|HHWXڒ+Y.@J_\b5h`W$h0rk|΂ck4jn@q`isj)Ln|֑B ~̲h^`OJQJo(hHh  ^ `OJQJ^Jo(hHoh  ^ `OJQJo(hHhxx^x`OJQJo(hHhHH^H`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh 88^8`5hH.h^`OJQJo(hHh  L ^ `LhH.h   ^ `hH.h xx^x`hH.h HLH^H`LhH.h ^`hH.h ^`hH.h L^`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`CJOJQJaJo(hHh ^ `OJQJ^Jo(hHoh ^ `OJQJo(hHhx^x`OJQJo(hHhH^H`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`CJOJQJaJo(hHh^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh ^`o(hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH.hhh^h`OJQJo(hHh@ @ ^@ `OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHhPP^P`OJQJo(hHh  ^ `OJQJ^Jo(hHoh^`OJQJo(hHh ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(hh^h`5o(. ^`hH. pLp^p`LhH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hH8^`OJQJo(hH888^8`OJQJ^Jo(hHo8^`OJQJo(hH8  ^ `OJQJo(hH8  ^ `OJQJ^Jo(hHo8xx^x`OJQJo(hH8HH^H`OJQJo(hH8^`OJQJ^Jo(hHo8^`OJQJo(hHh^`OJQJo(hHhP^`POJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh ^ `OJQJ^Jo(hHoh ^ `OJQJo(hHhx^x`OJQJo(hHhH^H`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`B*OJQJo(phhHh"^`B*OJQJ^Jo(phhHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh ^`OJQJo(h ^`OJQJo(oh pp^p`OJQJo(h @ @ ^@ `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h ^`OJQJo(oh PP^P`OJQJo(h^`OJQJo(hHh  ^ `OJQJ^Jo(hHoh  ^ `OJQJo(hHhxx^x`OJQJo(hHhHH^H`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHhP^`PB*OJQJo(phhHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJo(hHhxx^x`OJQJo(hHhHH^H`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh  ^ `OJQJo(hHh  ^ `OJQJo(hHhxx^x`OJQJo(hHhHH^H`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hH 88^8`o(hH.h^`B*OJQJo(phhHh $ $ ^$ `o(hH. @ @ ^@ `hH. ^`hH. L^`LhH. ^`hH. ^`hH. PLP^P`LhH.h^`OJQJo(hHh^`OJQJ^Jo(hHohpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohP^P`OJQJo(hHh 88^8`OJQJo(h ^`OJQJo(oh   ^ `OJQJo(h   ^ `OJQJo(h xx^x`OJQJo(oh HH^H`OJQJo(h ^`OJQJo(h ^`OJQJo(oh ^`OJQJo(h^`OJQJo(hHhP^`POJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHhP^`POJQJo(hHhpp^p`OJQJo(hHh@ @ ^@ `OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJQJ^Jo(hHohPP^P`OJQJo(hHh  ^ `OJQJo(hHh^`OJQJ^Jo(hHoh!!^!`OJQJo(hHh  ^ `OJQJo(hH   ^ `OJQJo(o xx^x`OJQJo( HH^H`OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o X X ^X `OJQJo( egq#l}(s>+6784ais)Դ+?۱%𲵱#-$a>                 Qi                                                      @0                         pV{                           z                          rl t                                   @0        @0                          @ @ @" C7~CBc;,9>4]J  .i3WpdgOwSXg/L:CpzVtw % a- *I J J  A W Z z a `c ,} !j n g0 ? X Y )9mx0Bj   XH7Uz,3Ritmw[dZcxg%3l9lTUo?6 _5zM0QjPc==yT :.%Q^c~(U7Ol :kmq0@#xb z$ Y!Vw!W"2y"J #0#6#ed#f#;%m%*&BH&Gd&X'['1h'((F(S)(uA()$+)[)u+4,A-R-e}-..(.14.9.Lh.|.-/{D/P/z/|/bC0u12W23H3Q3L_3_3Q#4]4K 5>D5uQ58|566{+6`m6z 7@7\8a8X 9S>97c9 ::/1:2<:g]:k:J;2<!=]f>z>ʶ???UZʰ')(հ}ѶQ¶+'o74>),=>ݱ#)TAᰭM1NMPM*N[N{NH{N/O8O_OdO~P9PJQBRSKSN$S^S TTX/TMTVUw"VDVrVWZWIHYLYY{Y6Z^Q[%\P\|\~\=5]:]^^&^W^!u^>`&k`9ajAaCa:Nalaxakb\bbLbfb!c 9cHcIctrceeeLe)PeQe\ereve+f f-fccf2g?gLgs hh!hF^h i i i)iz:i:idijBjRMj:HkoKkSkzyk lfl!l$l#Nlnlm/m6+nKnoCoOFoFoT"pz1p?p q %rIrVxr%sfsfqs~st0:t}]tvtvtztS)uAuDuKuPu7v%vxfExcIxyJy*VyC|y(.zEz=Tzvz{[|3=|h|Vp|- }8}Z}`}"~6~5;~{~~1*9<WPc2< :})+},i.`Xp:Iamj#t2J^h0{U1YGLO/qt]uv(:EL N1K3B= ^%i7Yi4 5`7G(t9UE=Jxmo##H'*4NWlOFX5?:X\'C\gss 3[J )\@$'/5Z 'b_c */F.r .BbTGDT?oZ Jut0_4kk21=a$w.H1F KPR4QUX+X84o]Mv?gBJ\ Wg>*<EU\vFgo5p?g#_xVp6|>;ұ668dzݴ@q<sd;:W<GSpYNi 1w?Q7iMZFW3c#stv=kE#2DQxp.2N5? IJ$Qq~CXSy, >PFUZ !;<TYa]ZxBN bSXe(BbMROZb^e]}&q\ ,Mtx y(fO""%.+eBLgD {NZVoScAj "B mwE~(3>QDm|*Fo6q cZO?B]x-)Kou?(6sDXZQ_'.]o6tO*=VX^9#KedihmkShFRyK&OT0&(fYu '.T7auxyw7v<\ 1~k":&>KL; _Xp6u"x~+3 Jwbt/Po-&PQr+w8 I8`,Q]k}J7m;A9SMh18XbZrt@@Unknown G* Times New Roman5Symbol3. * Arial7.@Calibri3*Ax TimesA"GenevaArial5. .[`)Tahoma;Wingdings?= *Cx Courier NewA$BCambria Math"qhZyIy'F ll824 3qHP0u2! xx MODEL CONSENT FORMRobert O. Webster, Ph.D.1Melissa Fitzgerald [Office of Research Integrity]                         Oh+'0  \h    MODEL CONSENT FORMRobert O. Webster, Ph.D.Links fixed.Normal4Melissa Fitzgerald [Office of ˻ֱ Integrity]13Microsoft Office Word@_@~@ Qvt@G"w՜.+,D՜.+,T hp  Saint ˻ֱ Universityl MODEL CONSENT FORM Title 8@ _PID_HLINKSA arRightsCOSTS CONF8rDhttps://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html CONF ~CONF {CONF xCONFKu Section5rirRISrioRISrilRISLi Section2Lf Section2Lc Section2L` Section2L] Section2LZ Section2LW Section2puTPURQINTRO.8Nhttps://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/guidelines_lar.docx^Kmailto:irb@slu.eduYHtel:314-977-5767!Emailto:ogccontracts@slu.eduBhttps://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/consent_addendum_employee_payment.docxlb?paymenta|<costsandpayment+*9https://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/nih_clinical_trial_definition.docxco6COCwk3MandatedReport0releaseofresearchresultskt- datasharing *resereccontid' benefitsxc$breachCertConfd{!breach interview futureusefa AudioVideo followupcuinterviewquestionnairemlScreeningprocedures}u ParticipatinginOtherStudies  Deceptioneehttps://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/consent_key_information_examples.docx introduction7https://www.slu.edu/research/faculty-resources/research-integrity-safety/institutional-review-board-irb/irb_assets/hipaa_authorization_form.doc  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-.0123456789:;<=>?@ABCDEFGHJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~Root Entry Fp8w@Data /31TableIWordDocument \SummaryInformation(DocumentSummaryInformation8lMsoDataStore/d8wm8wMNZNUSDS2Q==2/d8wm8wItem  PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q